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CHAPTER 1: GENERAL INTRODUCTION 
 
1.1 Hepatic steatosis and non-alcoholic fatty-liver disease (NAFLD) 
 Fatty liver or hepatic steatosis is a pathological condition characterized by excessive 
accumulation of triglycerides (TGs) in the form of small (microvascular) or large 
(macrovascular) lipid droplets inside hepatic cells in amounts > 5-10% of total liver weight 
(Weiss et al., 2014). A healthy liver can become fatty due to several factors. Some of the 
causative agents of steatosis are high alcohol consumption, pregnancy, toxins, virus, such as 
hepatitis A and B, and use of drugs like aspirin, steroids, tamoxifen and tetracycline (Tolman 
and Dalpiaz, 2007). Steatosis occurring in the absence of any significant alcohol consumption, 
drugs or viruses is known as NAFLD (Loomba and Sanyal, 2013). Due to its frequent 
association with metabolic disorders such as obesity, diabetes mellitus, and dyslipidemia, 
NAFLD is also considered as the hepatic manifestation of metabolic syndrome (Loomba and 
Sanyal, 2013). 
 According to a 2012 report, the prevalence of NAFLD in the general USA population 
is about 20%-30% (Bedogni et al., 2014) and 34% in the population of the 14 European 
countries (Blachier et al., 2013). Similarly, studies from Japan, Hong Kong, Taiwan, Indonesia, 
and India show the prevalence of NAFLD to be 9-14%, 16%, 11-41%, 30% and 5-28% 
respectively (Parkash and Hamid, 2013). Further, NAFLD has higher prevalence in obese or 
diabetic patients with rates reaching up to 90% in morbidly obese subjects (LaBrecque et al., 
2014). Additionally, studies from diverse populations, such as Chinese, European and 
Taiwanese show that NAFLD is present in a disproportionately higher percentage of obese 
children compared to the general population (Wiegand et al., 2010; Yang and Huang, 2010; 
Fan, 2013). This high rate of pediatric NAFLD is extremely concerning given the sharp rise in 
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childhood obesity, even in underdeveloped countries where many of the children used to be 
underweight.  
1.2 Pathogenesis of NAFLD          
 NAFLD is a progressive disease and incorporates a wide spectrum of liver 
abnormalities that range from hepatocellular steatosis, steatohepatitis, fibrosis and ultimately, 
cirrhosis (Dowman et al., 2010). Pathologically, it occurs as two distinctive forms. The first 
one is the simple hepatic steatosis, also known as non-alcoholic fatty liver (NAFL), which is a 
benign condition very common in obese people, and is almost non-progressive (Masarone et 
al., 2014). In 5 - 20% of these patients, NAFL develops into a more severe and progressive 
form known as non-alcoholic steatohepatitis (NASH), which features hepatic swelling, and is 
histologically indistinctive from alcohol-induced hepatic steatosis (Weiss et al., 2014). 
Development of NAFL and its progression to NASH is often described by two-hit hypothesis, 
where the ‘first hit’ is the lipid accumulation in hepatocytes resulting from an imbalance in 
inflow of lipids into liver and amounts being degraded or exported from liver. The ‘second hit’ 
is defined by generation of oxidative stress and inflammation caused by infiltration of 
cytokines that results in steatohepatitis (Dietrich and Hellerbrand, 2014). 10–20% of NASH 
patients also develop fibrosis due to chronic liver injury and wound healing. NASH affects 
around 2-3% of total world population and progresses to hepatic cirrhosis in <5% of patients, 
which affects around 0.05–0.3% of the general world population (Weiss et al., 2014). The 
endpoint of NASH prognosis is hepatocellular carcinoma, which is a fatal unless the patient 
receives liver transplant.  
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1.3 Risk factors for NAFLD 
 NAFLD development is a complex process that involves intricate interactions between 
host and environmental factors. As mentioned above, one of the major risk factors for NAFLD 
is the metabolic syndrome. Obesity, insulin resistance, and diabetes are independent predictors 
of NAFLD and are very closely associated with NAFLD prevalence (Younossi et al., 2011). 
For instance, studies show that prevalence of NAFLD in the general US population is between 
27-34% (LaBrecque et al., 2014); however, prevalence of NAFLD is around 70% or more in 
patients with obesity and type-2-diabetes mellitus (T2DM) and 50% in patients with 
hyperlipidemia, and around 60% of obese patients undergoing gastric bypass surgery display 
the more severe form of NAFLD (Dietrich and Hellerbrand, 2014).  Age is another important 
risk factor for NAFLD development. The older population has higher NAFLD prevalence with 
rates peaking at the age of 40s and 60s in men and in women respectively (Mishra and 
Younossi, 2012). Also, benign NAFL has larger likelihood of progressing into NASH in older 
patients leading to greater mortality in elderly compared to the younger patients (Ong et al., 
2008). However, age-associated risk for NAFLD is confounded by the fact that prevalence of 
other independent risk factors, such as obesity and metabolic syndrome, is also higher in older 
patients.    
 Gender is another risk factor for NAFLD, and several studies across different 
population groups show that men are at greater risk to develop NALFD than women (Chen et 
al., 2008; Williams et al., 2011; Mishra and Younossi, 2012). A retrospective study of patients 
who underwent gastric bypass surgery found that out of 58 men and 307 women, 60.3% men 
had NASH compared to 30.9% of women (Arun et al., 2006), even though both genders had 
similar composition of other risk factors, such as age, obesity and other metabolic syndromes. 
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Risk for NAFLD is also associated with race and ethnicity. In the USA, the prevalence of 
steatosis is highest in Hispanics followed by whites and then black (Browning et al., 2004). 
Even though the higher prevalence of hepatic steatosis in Hispanics was associated with a 
higher percentage of obesity and insulin resistance, these factors were not associated with the 
lowest prevalence in Blacks (Browning et al., 2004). Further, NAFLD patients in Asians 
countries usually have lower rates of obesity compared to the NAFLD patients in western 
countries. According to a report in Japan, only 20-30% of NAFLD patients were obese, 
whereas in USA, almost 60-80% of NAFLD patients suffered from obesity (Eguchi et al., 
2012).  
 The discovery of ethnic differences in NAFLD prevalence as well as reports of familial 
clusters of NAFLD patients (Willner et al., 2001) suggest that genetic susceptibility is another 
important risk factor for NAFLD. Several studies indicate that polymorphisms in the 
adiponutrin/patatin-like phospholipase-3 (PNPLA3) gene, which encodes a 481 amino acid 
protein related to adipose TG lipase, to be one of the most important contributors to variation 
in NAFLD prevalence among different populations (Anstee et al., 2011). One of the variants 
of the gene, rs738409, is significantly associated with increased TG content in human liver and 
elevated levels of serum transaminase levels, which is an indicator of hepatic injury (Romeo 
et al., 2008). This variant is also a strong risk predictor for NAFLD in Asian and Hispanic 
populations (Romeo et al., 2008; Zhang et al., 2015a). Another variant of the same gene, 
rs6006460, however, seems to have protective effects against NAFLD, and is abundant in 
African–Americans associated with low NAFLD prevalence but is rare in European–
Americans and Hispanics (Romeo et al., 2008).  
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1.4 Hepatic TG accumulation during NAFLD 
 Hepatic accumulation of TGs is the hallmark of NAFLD. Under normal physiological 
conditions, fatty acid-flux through the liver is maintained in a steady state with only small 
amounts of TGs being stored in hepatocytes (Kawano and Cohen, 2013). Fats from diet are 
assembled as triglyceride-rich chylomicrons, which are secreted into plasma and are primarily 
distributed to adipose tissues.  These circulating chylomicrons can also undergo lipolysis to 
generate non-esterified fatty acids (NEFAs) that are delivered to liver, and are taken up by the 
hepatic plasma membrane receptors, such as fatty acid transport proteins (FATPs) and fatty 
acid translocase (FAT; CD36) (Reddy and Sambasiva Rao, 2006; Kawano and Cohen, 2013). 
When there is abundance of carbohydrates, fatty acids are also synthesized in liver by de novo 
lipogenesis. Fatty acids acquired either through diet or lipogenesis are esterified and used as 
substrates for TG biosynthesis in liver, which are either stored within the hepatocytes or 
exported in the form of very low-density lipoproteins (VLDL) particles into the bloodstream. 
Under fasting conditions, fatty acids are degraded through oxidation, primarily in mitochondria 
and peroxisomes, in order to release energy in the form of ATP (Browning and Horton, 2004). 
Any imbalance between acquisition of fatty acid and its clearance from hepatocytes, either 
through export or oxidation, disturbs lipid homeostasis in liver leading to intracellular 
accumulation of TGs.  
 The major mechanisms behind a metabolic imbalance in liver include: 1) increased 
supply of fatty acids from plasma, either from higher intake of dietary fats or from a higher 
rate of chylomicron lipolysis; 2) increased rate of de novo lipogenesis; 3) reduced rate of fatty 
acid oxidation; 4) decreased secretion of TGs in the form of VLDL particles (Browning and 
Horton, 2004; Kawano and Cohen, 2013). Both extra-hepatic and hepatic events influence the 
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above processes in order to cause perturbations in hepatic lipid homeostasis.  The major extra-
hepatic factors include higher intake of dietary fat, increase in the body fat mass due to visceral 
and peripheral obesity that leads to development of insulin resistance and makes adipocytes 
less susceptible to the antilipolytic effects of insulin. This increases the plasma pool of NEFAs, 
and therefore more fatty acids end up being taken up by the hepatocytes.  (Anderson and 
Borlak, 2008). Intra-hepatic factors mostly include changes in the expression or activity of 
genes that are responsible for fatty acid uptake, lipogenesis, fatty acid oxidation, TG storage 
and export from the liver.  These genes and the cellular processes they regulate are controlled 
by both transcriptional and post-transcriptional modifications. An important group of 
molecules involved in transcriptional regulation of hepatic lipid metabolic processes are 
nuclear receptors and are described below. 
1.5 Nuclear receptors: Lipid metabolism and NAFLD 
 Nuclear receptors (NRs) are ligand-activated transcription factors that regulate a broad 
range of metabolic, detoxifying, and regulatory processes through complex transcriptional 
networks in response to diverse ligands (natural or synthetic), including lipids, bile acids, 
vitamins, xenobiotics, hormones, drugs, and toxins (López-Velázquez et al., 2012). Several of 
these NRs, such as the peroxisome proliferator-activated receptors (PPARs), farnesoid X 
receptors (FXR), liver X receptor (LXR), constitutive androstane receptor (CAR) and pregnane 
X receptor (PXR) are involved in transcriptional regulation of key hepatic lipid-metabolizing 
genes that regulate several critical metabolic processes, which are often dysregulated during 
NAFLD, such as lipolysis, fatty acid uptake, oxidation, storage, and export (Wagner et al., 
2011). NRs play central roles in hepatic homeostasis, and because of their involvement in the 
metabolism of fatty acid, cholesterol and bile salts, hepatic inflammation and fibrosis, they are 
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regarded as important therapeutic targets for NAFLD or NASH treatment (George and Liddle, 
2008; Machado and Cortez-Pinto, 2014; Mazzoccoli et al., 2014). Involvement of some of the 
NRs, such as FXR, CAR and PPARs in hepatic lipid metabolism as well as in NAFLD 
pathogenesis are described below.  
1.5.1 Farnesoid X receptor  
 One of the NRs that is emerging as a major player in NAFLD pathogenesis and 
treatment is FXR. It is a bile acid receptor that is activated by bile acids, such as cholic acid 
(CA) and chenodeoxycholic acid (CDCA). FXR is highly expressed in tissues like liver, 
kidneys and intestines. In addition to regulating bile acid homeostasis, FXR plays important 
roles in hepatic lipid metabolism especially by regulating lipogenesis. Hepatic fatty acid 
synthesis is mostly controlled by the sterol regulatory element binding protein 1c (SREBP-1c), 
which regulates the expression of several important lipogenic genes including fatty acid 
synthase (FAS) and stearoyl-coenzyme A desaturase 1 (SCD1)(Xu et al., 2014). Activation of 
FXR increases the expression of the short heterodimer partner (SHP), which downregulates 
expression of the liver X receptor (LXR) and its target gene SREBP-1c. Thus, FXR activation 
suppresses expression of SREBP-1c target enzymes through the SHP-LXR-SREBP-1c 
pathway leading to reduced lipogenesis, and therefore less fatty acid is available as precursor 
for triglyceride biosynthesis (Watanabe et al., 2004). Also, FXR has been shown to suppress 
hepatic lipogenesis and TG accumulation through a SREBP-1c-independent pathway that 
involves FXR-mediated inhibition of the carbohydrate response element-binding protein 
(ChREBP), which is another crucial gene responsible for hepatic glucose and lipid metabolism 
(Li et al., 2013). FXR activation has also been shown to increase clearance of hepatic TGs by 
modulating expression of apolipoproteins (Xu et al., 2014) and enhance fatty acid oxidation 
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by inducing the expression of PPARα and its target gene, carnitine palmitoyltransferase 1 
(CPT1) (Pineda Torra et al., 2003). 
 In NAFLD patients, hepatic expression of FXR is decreased while the expression of 
LXR, SREBP-1c and FAS are increased, which is associated with increased TG synthesis 
(Yang et al., 2010). Expression of FXR is also suppressed in liver of obese mice and FXR-null 
mice develop spontaneous hepatic steatosis (Xu et al., 2014). One of the most studied FXR 
agonists is INT-747 (also known as Obeticholic acid (OCA)), a synthetic bile acid analogue 
and a 6α-ethyl derivative of CDCA, which is reported to suppress steatohepatitis and improve 
glucose and insulin tolerance and lower the expression of lipogenic genes animal models of 
steatosis (Patel et al., 2015). In a clinical study where NAFLD patients with type 2 diabetes 
mellitus were given either 25 (n=20) or 50 mg (n=21) OCA for 6 weeks, increase in insulin 
sensitivity, and reduction fibrosis and inflammation markers were observed. OCA has also 
been studied in a larger clinical trial known as the farnesoid X receptor ligand obeticholic Acid 
in non-alcoholic steatohepatitis (FLINT) study where NASH patients were treated with 25 mg 
OCA for 72 weeks (Neuschwander-Tetri et al., 2015). Results showed that OCA improved 
liver histology in 45% of the patients compared to the observed 21% in control group. Decrease 
in the serum alanine aminotransferase levels, a marker for liver damage accompanied these 
effects. However, OCA caused pruritus in 23% of the patients and also led to 20% increase in 
the LDL-cholesterol levels, which required withdrawal of treatment.  This increase in risk for 
atherosclerosis suggests that beneficial advantage of long-term OCA treatment against 
NAFLD/NASH needs to be further evaluated.   
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1.5.2 Peroxisome proliferator-activated receptors  
 PPARs are another group of NRs that have been shown to play an important role in 
steatosis and pathogenesis of NAFLD. While the three PPAR isotypes, PPARα, PPARβ/δ, and 
PPARγ have different tissue and ligand specificity, they all are involved in regulating the 
expression of genes involved in overall energy homeostasis. PPARγ is abundant in adipose 
tissues, PPARβ/δ has ubiquitous expression and PPARα is predominant in liver (López-
Velázquez et al., 2012). In hepatocytes, PPARα acts as a lipid sensor that detects increases in 
free fatty acids, and then transcriptionally induces fatty acid oxidation by regulating expression 
of genes involved in mitochondrial, peroxisomal and microsomal oxidation (Sambasiva Rao 
and Reddy, 2004). PPARα also modulates expression of fatty acid binding and transport 
enzymes, lipases and apolipoproteins in hepatocytes (Mandard et al., 2004; López-Velázquez 
et al., 2012).  
 Involvement of PPARα in NAFLD/NASH pathogenesis is supported by studies on 
PPARα deficient animal models where absence of PPARα is associated with reduced hepatic 
fatty acid oxidation and development of severe hepatic steatohepatitis, which can be reversed 
by administration of PPARα agonists (Sambasiva Rao and Reddy, 2004). Expression of 
PPARα is also suppressed in steatotic human liver. In the liver of obese and NAFLD patients, 
hepatic TG accumulation is associated with increased expression of SREBP-1c and FAS, while 
the mRNA level of PPARα is suppressed, resulting in metabolic imbalance followed by 
steatosis due to a higher rate of lipogenesis than lipid oxidation (Pettinelli et al., 2009). In 
preclinical studies, pharmacological activation of PPARα by fibrates, such as fenofibrate 
suppresses hepatic TG accumulation and ameliorates steatosis in animal models (Tailleux et 
al., 2012). However, such strategies have not been successful in clinical studies yet, and 
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activation of PPARα has not produced conclusive results, which might be partially attributable 
to insufficient sample size and incomplete data (Tailleux et al., 2012; Machado and Cortez-
Pinto, 2014). However, this discrepancy could also be the result of the species-specific 
differences that exist in PPARα activity between rodents and human regarding expression, 
ligand-responsiveness and identity of its target genes (Sambasiva Rao and Reddy, 2004). 
Therefore, further studies are required to determine the usefulness of targeting PPARα for 
pharmacological intervention against NAFLD.  
1.5.3 Constitutive androstane receptor 
 The constitutive androstane receptor is mostly known for its role in xenobiotic 
metabolism; however, it is also responsive towards endogenous metabolites, such as 
androstane, progesterone and estrogen, and is reported to be involved in regulation of energy 
homeostasis, including lipid and glucose metabolism (Wada et al., 2009). CAR has been shown 
to inhibit lipogenesis by transcriptionally increasing levels of the Insig-1 protein, which in turn 
reduces the levels of active SREBP-1c and thereby, suppresses expression of lipogenic genes 
that are transcriptional target of SREBP-1c (Roth et al., 2008). Additionally, during fasting, 
CAR has been shown to compete with PPARα for the binding sites on the promoter of PPARα-
target gene 3-hydroxyacyl CoA dehydrogenase, which is involved in the peroxisomal β-
oxidation (Kassam et al., 2000).  In rodents, pharmacological activation of CAR has been 
shown to produce contradictory results regarding development of steatosis. Depending on the 
animal model, CAR has been shown to either have no effect on hepatic lipid accumulation, 
induce abnormal de novo lipogenesis and insulin resistance, increase serum TG and hepatic 
lipogenesis, or suppress lipogenesis, increase β-oxidation and improve insulin sensitivity (Naik 
et al., 2013). Further, SREBP-1c, which is increased in steatotic liver, has been reported to 
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impair CAR-mediated activation of its target genes by hindering CAR’s ability to interact with 
co-activators, suggesting that CAR activity is itself altered during NAFLD (Roth et al., 2008). 
 As discussed above, NRs, such as PPARs, CAR and FXR regulate various critical 
metabolic processes involved in the development of hepatic steatosis and pathogenesis of 
NAFLD. Given their roles in lipid metabolism and suggestions of cross talk between different 
NRs, they could be attractive candidates for pharmacological interventions against NAFLD.  
1.6 Farnesol: An isoprenoid-derivative of the mevalonate pathway 
 The isoprenoid pathway, also known as the mevalonate pathway for cholesterol 
biosynthesis, is the source of several important metabolic intermediates that are involved in a 
variety of biological processes (Edwards and Ericsson, 1999). As depicted in figure 1, the first 
step of the pathway involves condensation of two molecules of acetyl-CoA to acetoacyl CoA, 
which is then metabolized by the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-
CoA) synthase to HMG-CoA (Figure 1). HMG-CoA-reductase (HMGCR) reduces this 
compound to mevalonate, which is then phosphorylated by mevalonate kinase to produce 5-
phosphomevalonate. Additional phosphorylation and decarboxylation of 5-
phosphomevalonate leads to production of isopentenyl pyrophosphate (IPP), which is the basic 
isoprene subunit used to build several other isoprenoid compounds. Isomerization of IPP 
produces dimethylallyl pyrophosphate (DMAPP), which together with IPP is condensed by the 
enzyme farnesyl pyrophosphate synthase (FPPS) to the 10-carbon geranyl pyrophosphate 
(GPP). A second molecule of IPP is then added to GPP by FPPS producing farnesyl 
pyrophosphate (FPP), which is the major branch-point intermediate in the mevalonate 
pathway.  
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 Under basal conditions, the majority of the FPP is metabolized by the enzyme squalene 
synthase to produce squalene, which is the first committed step towards synthesis of 
cholesterol. Alternatively, FPP and IPP are combined by the enzyme geranylgeranyl 
pyrophosphate (GGPP) synthase to form GGPP, a twenty-carbon compound. FPP also function 
as the precursors to several longer chain isoprenoids including ubiquinone (coenzyme Q), 
dolichol, dolichyl phosphate, heme O, heme A, and isopentenyl tRNA (Goldstein and Brown, 
1990). Additionally, FPP and GGPP function as substrates for protein prenylation reactions, 
which are important post-translational modifications that are required for cellular signaling by 
small GTPases (Zhang and Casey, 1996). 
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Figure 1. Schematic of mevalonate pathway for cholesterol synthesis.  Two molecules of 
acetyl-CoA are utilized as the initial substrates to synthesize cholesterol through a series of 
enzymatic reactions. Farnesol is one of the isoprenoids derivatives of the pathway, which is 
produced by dephosphorylation of the branch point intermediate, farnesyl pyrophosphate 
(FPP). Farnesol can be sequentially metabolized to produce dicarboxylic acids, which are 
excreted through urine. 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), isopentenyl-
diphosphate delta isomerase 1 (IDI1), isopentenyl-diphosphate delta isomerase 2 (IDI2), 
geranylgeranyl diphosphate synthase 1 (GGPPS), farnesyl pyrophosphate synthase (FPPS), 
squalene synthase (SQS), squalene monooxygenase (SM), lanosterol synthase (LS).  
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One of the non-sterol derivatives of FPP is farnesol, which produced by sequential 
dephosphorylation of FPP by phosphatases. Farnesol is a 15-carbon acyclic sesquiterpene 
alcohol (C15H26O) and is the building block of most of the acyclic sesquiterpenoids. Farnesol 
is colorless under standard conditions and is hydrophobic, therefore miscible with oils. Apart 
from its endogenous synthesis in animals, farnesol can be acquired via consumption of fruits 
and aromatic plants, including citrus, sage, spearmint, lemon grass, strawberries, tomatoes, 
peaches and plant-based essential oils. (Duncan and Archer, 2008). It has a sweet aroma and 
is routinely used as a fragrance in perfumes.  
1.6.1 Physiological roles of farnesol 
 Farnesol and its metabolites (collectively known as farnesoids) are involved in several 
biological processes. Farnesol has been shown to mediate anti-tumor and chemotherapeutic 
responses in human cancer cell lines such as lung carcinoma, leukemia, oral squamous 
carcinoma, colon cancer and pancreatic adenocarcinoma (Rioja et al., 2000; Joo et al., 2007; 
Wiseman et al., 2007; Au-Yeung et al., 2008; Scheper et al., 2008). Similar results have also 
been observed in in vivo animal studies against hepatocellular carcinoma and pancreatic 
cancer. (Burke et al., 1997; Crowell, 1999; Burke et al., 2002; Ong et al., 2006). Many of these 
anti-cancer properties of farnesol are the result of its anti-proliferative effect on cancer cells 
caused by cell-cycle arrest and induction of apoptosis (Joo and Jetten, 2010). Farnesol-
mediated apoptosis can occur through various cellular processes including regulation of HMG-
CoA reductase and CTP:phosphocholine cytidylyltransferase α (CCTα), generation of reactive 
oxygen species, activation of nuclear receptors, induction of endoplasmic reticulum (ER) 
stress, and activation of the NF-κB signaling pathway (Joo and Jetten, 2010). The IC50 value 
for anti-proliferative effect of farnesol varies between 25 to 250 µM, and neoplastic cells being 
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are more susceptible to farnesol-induced apoptosis than are non-malignant cells (Melnykovych 
et al., 1992; Adany et al., 1994). Farnesol is also involved in other biological processes such 
as microbial quorum sensing and biofilm formation (Albuquerque and Casadevall, 2012), 
synthesis of isoprenoids and protein prenylation (Crick et al., 1995; Thai et al., 1999), and 
cellular differentiation (Hanley et al., 2000). Farnesol also modulates the expression of several 
Phase I and Phase II drug-metabolizing enzymes, such as cytochrome p450 (1A, 2A1-3, 2B1/2, 
2C11/12, 2E1, 3A1/2, 4A1-3, 19) in rats, suggesting that farnesol can potentially affect drug 
metabolism and change drug efficacy or toxicity (Horn et al., 2005a). Finally, farnesol can also 
regulate lipid metabolic pathways, which is described in detail below. 
 1.6.2 Regulation of lipid metabolism by farnesol 
 Several in vivo and in vitro experiments in rodents and hepatoma cell lines have 
evaluated the effects of farnesol on lipid metabolism. Some of the first reports that implicated 
farnesol in regulation of lipid metabolic processes were studies where inhibition of the 
cholesterol biosynthesis pathway by squalene synthase inhibitors (SSIs) resulted in 
endogenous accumulation of farnesol. SSI inhibitors, such as zaragozic acid (squalestatin-1; 
SQ1), inhibit the enzyme squalene synthase (Figure 1) causing FPP accumulation and directing 
the pathway towards producing large amounts of farnesol-derived dicarboxylic acids (Bostedor 
et al., 1997; Vaidya et al., 1998). SQ1 was previously known to decrease serum cholesterol 
levels in marmosets, and lower cholesterol production from isolated rat hepatocytes and in rat 
liver (Baxter et al., 1992). Similarly, another SSI, RPR-107393, also reduced plasma 
cholesterol concentrations in rats (Amin et al., 1997). Taken together, these SSI-mediated 
effects on cholesterol levels, as well as the evidence that treatment with SQ1 causes increases 
in farnesol and its metabolites, suggested that farnesol or its derivatives could be involved in 
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SSI-mediated effects on cholesterol metabolism. Indeed, farnesol was implicated as the non-
sterol derivative of the mevalonate pathway that degraded HMGCR and inhibited cholesterol 
synthesis through feedback regulation (Correll et al., 1994; Keller et al., 1996).  
 Several other studies that evaluated the effects of SSIs on lipid metabolism followed 
these findings. The SSI YM-53601 not only lowered plasma non high-density lipoprotein 
(HDL)-C levels in rhesus monkeys, but also significantly reduced plasma TG levels (Ugawa 
et al., 2000). Similarly, Hiyoshi et al. showed that treatment with ER-27856, a potent SSI 
prodrug, decreased plasma cholesterol levels in rabbits through a low-density lipoprotein 
(LDL) receptor-independent mechanism, and also reduced plasma TG levels and TG 
biosynthesis (Hiyoshi et al., 2001). Further, the SSI TAK-475 reduced nonHDL-cholesterol 
and TG levels in marmosets, cynomolgus monkeys, beagle dogs and Wistar fatty rats. In rats, 
the lipid-lowering effect of TAK-475 was associated with suppression of hepatic TG secretion 
and upregulation of LDL receptors (Nishimoto et al., 2003). These SSI-mediated decreases in 
cholesterol and TG levels were later shown to be mediated via accumulation of intracellular 
farnesol and its derivatives in primary cultured rat hepatocytes (Hiyoshi et al., 2003). Also, 
direct treatment with farnesol suppressed TG and cholesterol biosynthesis, while SSIs 
suppressed fatty acid biosynthesis as well (Hiyoshi et al., 2003). The isoprenols farnesol and 
geranylgeraniol regulated expression of several hepatic lipid metabolic genes including 
adipocyte fatty acid-binding protein (aP2), carnitine palmitoyltransferase 1 liver (CPT1A) and 
acyl-CoA synthetase (ACS) in 3T3-L1 and HepG2 cells (Takahashi et al., 2002), which 
provided some mechanistic insights behind farnesol-mediated regulation of lipid metabolism. 
Additionally, oral administration of farnesol lowered serum TGs, increased fatty acid oxidation 
rate and suppressed lipogenesis in rats (Duncan and Archer, 2008). In the same study, farnesol 
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upregulated expression of the fatty acid oxidation enzymes, CPT1A and fatty acyl-CoA 
oxidase (ACOX) and suppressed mRNA expression, protein levels and activity of the lipogenic 
enzyme FAS. Finally, in mice, co-administration of farnesol with high-fat diet lowered serum 
glucose and hepatic TG levels compared to high fat-only fed animals and farnesol treatment 
suppressed TG biosynthesis (Goto et al., 2011).  Genes responsible for fatty acid oxidation, 
such as CPT1A and ACS were also upregulated, while expression of genes regulating 
lipogenesis such as FAS and SREBP-1c were suppressed in farnesol-treated animals. These 
data showed that in rodents, farnesol has hypotriglyceridemic properties that are mediated via 
suppression of TG and fatty acid synthesis and upregulation of fatty acid oxidation, and 
demonstrates the potential of farnesol or its derivatives to be used as a therapeutic approach 
against hyperlipidemia and its pathophysiological consequences.  
1.6.3 Effect of farnesol on nuclear receptors 
 Studies have shown that farnesol modulates cellular processes through activation of 
nuclear receptors, such as PPARα and FXR in rodents. In the H4IIEC3 (rat hepatoma) cell line, 
farnesol increased activity of the PPARα target gene ACOX, and both farnesol and its 
derivative, farnesoic acid, increased the PPAR-response element (PPRE)-dependent ACOX-
luciferase activity in CV1 cells that were co-transfected with a rat PPARα expression plasmid 
(O'Brien et al., 1996). In wild-type mice, topical farnesol treatment increased expression levels 
of the marker genes for terminal epidermal differentiation, which was absent in PPARα-/- 
animals (Hanley et al., 2000). These findings are further supported by data showing that 
farnesol treatment upregulated PPARα mRNA levels as well as expression of PPARα target 
genes in clone-9 cultured rat hepatocytes (Duncan and Archer, 2008). Additionally, dietary 
farnesol increased the expression of fatty acid oxidation genes in the livers of high fat-fed mice, 
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which are regulated via PPARα (Goto et al., 2011). This farnesol-mediated upregulation of 
fatty acid oxidation gene expression was absent in PPARα-/- mice.  
  Farnesol-mediated regulation of human PPARα has not been clearly elucidated; 
however, several studies show that farnesol can mediate PPRE-dependent transactivation as 
discussed below. In human keratinocytes, trans,trans-farnesol has been shown to activate 
PPRE-dependent luciferase activity and increase PPARα mRNA levels in normal human 
kidney epithelial (NHK) cells (Hanley et al., 2000). In CV1 cells, which is a cell line derived 
from kidney of African green monkey, farnesol induced both PPARα/GAL4 and 
PPARγ/GAL4 luciferase reporter activity (Hanley et al., 2000; Takahashi et al., 2002). 
Farnesol also increased PPRE luciferase activity when cells are cotransfected with full-length 
human PPARα and PPARγ cDNA in CV1 cells. Additionally, in human PPARα overexpressed 
HepG2 cells, farnesol treatment increased the expression of PPARα target genes ACS and 
CPT1A, suggesting that farnesol can potentially activate both PPARγ and PPARα-mediated 
responses in human (Takahashi et al., 2002). In HT-29 and HCT116 colon cancer cells, 
farnesol increased PPARγ promoter activity and farnesol-mediated anti-proliferative effects in 
these cells were suppressed in the presence of PPARγ antagonist (Au-Yeung et al., 2008). 
 Farnesol is a known FXR agonist (Forman et al., 1995a) and has been shown to regulate 
several physiological responses through FXR. Farnesol-mediated activation of FXR has been 
suggested to induce proliferation of MCF-7 breast cancer cells (Journe et al., 2008). Also, in 
mice, farnesol was found to suppress expression of the lipogenic genes SREBP-1c and FAS 
through FXR activation, and thereby decrease the intracellular pool of fatty acids that are 
substrates for TG biosynthesis. This effect was suggested to be the mechanism through which 
farnesol suppressed TG biosynthesis in mice independently of the PPARα pathway (Goto et 
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al., 2011). However, in rats, farnesol reduced FAS but not SREBP-1c mRNA levels, and down-
regulation of FAS by farnesol was caused by a 9-cis retinoic acid-mediated mechanism that 
involved down-regulation of retinoid X receptor (Duncan and Archer, 2008).  
 Recently, Moore et al. [29] have shown that activation of CAR in mice reduces 
lipogenic genes and increases the expression of genes involved in β-oxidation and suggested 
that CAR activation may be a suitable therapeutic approach to treat diabetes and fatty liver 
disease. Since accumulation of farnesoids has been shown to activate CAR-regulated genes, 
such as CYP2B1 in primary rat hepatocytes (Kocarek and Mercer-Haines, 2002), it is possible 
that farnesoid-mediated lowering of hepatic lipid may occur through CAR activation.  
1.7 HepaRG Cells: A hepatoma cell model to study human hepatic lipid metabolism 
 Primary human hepatocytes are regarded as the gold-standard cell culture model to 
study human hepatic functions. However, their unpredictable availability, batch-to-batch 
variability in viability and function, loss of certain differentiated properties over time in 
culture, failure to replicate, and relatively short lifespan makes it difficult to use them as a 
routine experimental model of human liver (Guillouzo, 1998). To overcome these difficulties, 
hepatoma cell lines, such as HepG2 cells, have been developed that retain some liver-specific 
properties. However, these hepatoma cell lines fail to capture the overall gene expression 
pattern that is found in human liver, such as for CYP, and NRs, such as PPARs and CAR, 
which makes them unsuitable for studying many aspects of normal human hepatic physiology 
(Aninat et al., 2006).  
 HepaRG is a recently developed bipotent hepatic cell line that was derived from a 
human hepatocellular carcinoma, and it expresses most of the liver-specific enzymes and high 
levels of CYPs (Guillouzo et al., 2007). When seeded at low density, undifferentiated HepaRG 
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cells grow into an elongated cell type that shows markers for hepatic progenitor cells. The 
undifferentiated HepaRG cells can be maintained in sub-confluent culture for many weeks and 
they fully retain their proliferative capacity (Aninat et al., 2006). After reaching confluency at 
around 10 days after plating, the cells show two distinct morphologies: one forming clusters 
of granular cells resembling hepatocytes surrounded by the second cell type that is more 
flattened and has clear cytoplasm. Upon addition of 2% DMSO to the culture medium, the 
hepatocyte-like cells are further differentiated into more granular cells that resemble mature 
hepatocytes with bile canaliculus-like structures and express hepatocyte-specific markers that 
can be maintained in culture for several weeks. The second group of flattened cells expresses 
markers for biliary epithelial cells. At confluency, the hepatocyte-like cells make up 50-55% 
of the total cell population. The unique feature of HepaRG cells compared to other hepatic cell 
lines, such as HepG2, is that HepaRG cells express most of the drug-metabolizing enzymes 
and other liver-specific genes, and therefore resemble primary cultured human hepatocytes 
more closely than do other human hepatic cell lines (Aninat et al., 2006; Hart et al., 2010; 
Gerets et al., 2012). Moreover, the fact that HepaRG cells can be cultured over multiple weeks 
allows extended studies of liver metabolism, xenobiotic toxicity, and other liver functions to 
be performed.  
 Comparative microarray analysis shows that upon DMSO stimulation, HepaRG cells 
express a vast number of genes similar to primary cultured human hepatocytes, including high 
mRNA levels of CYPs, such as CYP2B6, 3A4, 1A2, 2D6, and 4F3B (Aninat et al., 2006; 
Gerets et al., 2012; Samanez et al., 2012). In addition, HepaRG cells have been described as a 
suitable model to study hepatic lipid and glucose metabolism since they secrete TG and apo-B 
rich lipoprotein as well as express SREBP-1c and FAS that can be further induced by glucose 
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(Guillouzo et al., 2007; Samanez et al., 2012). Furthermore, HepaRG cells have been shown 
to have high and sustainable expression of NRs such as PPAR, CAR, FXR and pregnane X 
receptor (PXR) (Aninat et al., 2006; Samanez et al., 2012). PPARα agonist treatments have 
been shown to increase the expression of PPAR target genes, such as fatty acid binding protein 
(FABP4) and carnitine palmitoyltransferase 1 (CPT1), suggesting that the pathway is 
responsive to external stimulation (Rogue et al., 2012). Both FABP4 and CPT1 play important 
roles in lipid metabolism where they are regulate fatty acid transport across membranes and 
catalyze the rate-limiting step in β-oxidation respectively (Nguyen et al., 2008).  Therefore, 
HepaRG’s similarities to primary human hepatocytes, continual expression of hepatic enzymes 
for a considerable time in culture, presence of functional NRs in measurable amounts and 
functional lipid metabolic pathways support the use of this cell system to study farnesol-
mediated effects on human hepatic lipid homeostasis.  
1.8 Objective of the dissertation 
 The major objective of the research described below is to investigate the effects of 
farnesol on hepatic lipid metabolism in human liver under condition that leads to intrahepatic 
accumulation of triglycerides and to elucidate any underlying mechanisms behind such effects. 
As an overarching hypothesis, we propose the that farnesol treatment changes the 
expression of genes involved in human hepatic lipid homeostasis and that these changes 
occur through altering the activity of one or more of the nuclear receptors PPARα, FXR, 
and CAR. This hypothesis is based on the evidences described above that demonstrate 
farnesol’s ability to suppress TG accumulation in the hepatocytes of rodents and its capability 
to modulate the activity of the three nuclear receptors. The hypothesis would be tested through 
two specific aims.  
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1) Specific aim 1: To identify the farnesol-mediated changes in the expression of genes 
involved in lipid metabolism, where HepaRG cells will be treated with farnesol, and pathway-
based microarray analysis will be performed using a customized PCR Array for genes involved 
in hepatic lipid metabolism.  
2) Specific aim 2: To determine the roles of NRs in farnesol-mediated changes in human 
hepatic lipid-metabolizing gene expression. For this purpose, we will determine the identity of 
the potential receptor and the impact of its knockdown on farnesol-mediated effects on gene 
expression.  
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CHAPTER 2: FARNESOL SUPPRESSES TRIGLYCERIDE ACCUMULATION AND 
REGULATES HEPATIC LIPID METABOLISM THROUGH PEROXISOME 
PROLIFERATOR-ACTIVATED RECEPTOR ALPHA (PPARα) PATHWAY IN 
STEATOTIC HepaRG CELLS. 
2.1 Introduction 
 Intrahepatic triglyceride (TG) levels are regulated through a delicate balance between: 
1) the amount of free fatty acid that either enter hepatic cells from plasma or that is synthesized 
de novo and 2) the amount of fatty acid that is catabolized through oxidation or that is secreted 
into plasma as triglycerides (Koo, 2013). Any change in the balance between these complex 
metabolic pathways results in more fatty acid entering or produced in the hepatocytes than is 
eliminated, which increases intrahepatic fat content (Anderson and Borlak, 2008; Musso et al., 
2009). When TG accumulates inside hepatic cells to amounts > 5% of total liver weight, the 
liver is classified as steatotic (Bedogni et al., 2014). Hepatic steatosis occurring in absence of 
any significant alcohol use, drugs or viruses is the hallmark of non-alcoholic fatty liver disease 
(NAFLD) (Loomba and Sanyal, 2013), which is considered to be the hepatic manifestation of 
the metabolic syndrome (Angulo, 2007). Even though NAFLD has become the most common 
liver disease today with its worldwide prevalence ranging from 11 to 40%, there are no 
established therapeutic regimens except for weight loss (Kawano and Cohen, 2013).  
 Farnesol is a non-sterol isoprenoid that is produced endogenously through the 
dephosphorylation of farnesyl pyrophosphate (FPP), a key branch-point intermediate of the 
cholesterol biosynthetic pathway (Goldstein and Brown, 1990). Farnesol is also widely present 
in plants such as peaches, tomatoes, strawberries, corn and lemongrass (Duncan and Archer, 
2008). Physiologically, farnesol serves as the intermediate in the elimination of excess FPP 
and can also function as a signaling molecule in a variety of cellular processes, such as 
feedback regulation of sterol biosynthesis, vasoconstriction, apoptosis, cell proliferation, and 
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lipid metabolism (Correll et al., 1994; Edwards and Ericsson, 1999).  Regarding the latter, 
several in vivo and in vitro studies in rodents have shown that farnesol treatment improves 
metabolic abnormalities in obese animals, decreases expression of fatty acid synthesis genes, 
increases expression of fatty acid oxidation genes, and lowers TG levels in plasma and in 
cultured hepatocytes (Takahashi et al., 2002; Duncan and Archer, 2008; Goto et al., 2011). 
Similarly, farnesol and its metabolites have also been implicated in the TG lowering effects 
produced by inhibitors of squalene synthase, the enzyme that catalyzes the conversion of FPP 
to squalene, which is the first committed step in sterol biosynthesis (Hiyoshi et al., 2003). 
These studies suggested that farnesol might be useful as an early therapeutic strategy to 
alleviate steatosis and NAFLD progression.  
 Most of the regulatory effects of farnesol on lipid metabolism in the above studies were 
shown to be mediated through nuclear receptors such as the peroxisomal proliferator receptors 
(PPARα; NR1C1 and PPARγ; NR1C3), farnesoid X receptor (FXR; NR1H4) and retinoid X 
receptor β (RXRβ) (Takahashi et al., 2002; Duncan and Archer, 2008; Goto et al., 2011). These 
ligand-activated transcription factors regulate expression of several lipid-metabolizing genes 
involved in fatty acid oxidation, synthesis, uptake, storage, transport and elimination (Chawla 
et al., 2001; and and Moller, 2002; Wagner et al., 2011). While the above studies demonstrate 
that farnesol can produce beneficial effects on rodent hepatic lipid metabolism, the relevance 
to human is not clear, since activity of nuclear receptors can differ substantially across species 
(Gonzalez and Shah, 2008; Kiyosawa et al., 2008; Ross et al., 2010). Additionally, farnesol 
and/or its metabolites activate constitutive androstane receptor (CAR; NR1I3) in primary 
cultured rat hepatocyte (Kocarek and Mercer-Haines, 2002). However, whether CAR 
activation has any role in farnesol’s ability to regulate hepatic lipid metabolism has not yet 
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been studied, which is important given CAR’s involvement in lipid metabolism and its 
crosstalk with PPARα (Xiao et al., 2013). In this study, we used oleic acid (OA)-overloaded 
HepaRG cells as a model for human hepatic steatosis in order to determine farnesol’s effects 
on various lipid-metabolizing pathways as well as any involvement of PPARα, CAR or FXR 
signaling in the farnesol-mediated effects. We found that farnesol treatment lowered TG levels 
and increased fatty acid oxidation rate in the OA-overloaded HepaRG cells. Farnesol treatment 
also changed the expression of several lipid-metabolizing genes, including several that were 
not previously associated with farnesol treatment in rodent studies. Most of the farnesol-
mediated changes, especially those involved in mitochondrial β-oxidation, occurred via 
PPARα-dependent mechanisms.  
2.2 Materials and method 
Materials 
Trans,trans-farnesol, dimethyl sulfoxide (DMSO), and 6-(4-chlorophenyl)imidazo[2,1-
b][1,3]thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime (CITCO), 3-[2-[2-Chloro-4-[[3-
(2,6-dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methoxy]phenyl]ethenyl]benzoic acid 
(GW4064), oleic acid (OA), hematoxylin, Oil Red O (ORO), 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) and fatty acid free bovine serum albumin (FF-BSA) were 
purchased from Sigma Chemical (St. Louis, MO). 2-[[4-[2-[[(Cyclohexylamino)carbonyl](4-
cyclohexylbutyl)amino]ethyl]phenyl]thio]-2-methylpropanoic acid (GW7647) and N-((2S)-2-
(((1Z)-1-Methyl-3-oxo-3-(4-(trifluoromethyl)phenyl)prop-1-enyl)amino)-3-(4-(2-(5-methyl-
2-phenyl-1,3-oxazol-4 (GW6471) were purchased from Tocris (Minneapolis, MN). Williams’ 
medium E was purchased from Invitrogen (Carlsbad, CA), recombinant human insulin 
(Novolin R) from Novo Nordisk Pharmaceuticals, Inc. (Princeton, NJ), and TaqMan and 
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SYBR Green PCR master mix were purchased from Applied Biosystems (Foster City, CA). 
Additional materials were obtained from the sources listed below. [9,10-3H(N)]-OA was 
purchased from PerkinElmer (Waltham, MA). 
HepaRG cell culture and differentiation 
HepaRG cells were obtained from Biopredic International under a Material Transfer 
Agreement with INSERM-Transfert (Paris, France). The cells were plated at a density of 2.4 
X 104cells/cm2 on culture plates (6-well plates unless otherwise indicated) in HepaRG growth 
medium (Williams’ Medium E supplemented with 10% FBS, 5µg/ml insulin, 0.1M 
triamcinolone acetonide, and 100u/ml penicillin and 100ug/ml streptomycin) for 14 days 
followed by HepaRG differentiation medium 1 (HepaRG growth medium supplemented with 
1% DMSO) for 48 hours and HepaRG differentiation medium 2 (HepaRG growth medium 
supplemented with 2% DMSO) for a further 14 days. Culture medium was renewed every 2-3 
days. Differentiated HepaRG cells were then cultured in supplemented Williams’ medium E 
with 2% FBS for 72 hours. Drug the treatments were begun 96 hr after removal of HepaRG 
differentiation media and were done in DMSO-free serum-free HepaRG treatment media. Prior 
to treatment, all cells were maintained for 24 hr in serum-free supplemented Williams’ E 
medium (HepaRG treatment medium). Drugs were added to the culture medium as 
concentrated stock solutions (1000X) in ethanol or DMSO at the concentrations indicated in 
the individual figure legends.  
Farnesol and oleic acid treatments  
1000X Farnesol stocks (10, 30, 100, 300 and 1000 mM) were prepared in 100% 
ethanol. For farnesol treatments, the required volume of farnesol stock was added to 0.7% FF-
BSA in HepaRG treatment medium-2 and allowed to complex for 30 min. FF-BSA+ 0.1% 
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ethanol was used as a vehicle control for all farnesol studies.  For oleic acid (OA) treatment, 
OA was first complexed with to FF-BSA at a 6:1 molar ratio (OA: BSA). Briefly, an 8mM 
OA: FF-BSA stock was prepared by adding 4.52 mg OA into 1 ml of 8.8% FF-BSA solution 
in HepaRG treatment media-2, vortexed, and warmed at 370C until the cloudiness disappeared. 
Required volumes of stock were then diluted in HepaRG treatment media-2 to obtain the 
desired final OA concentrations.       
Measurement of cell viability 
The MTT assay was utilized to assess treatment effects on cell viability, as has been 
previously described in detail (Mosmann, 1983).  Briefly, MTT was dissolved at a 
concentration of 1 mg/mL in 1X phosphate buffered saline (PBS) and sterile-filtered prior to 
use.  At selected times following treatment, culture medium was replaced with 0.3 mL of MTT 
solution, and cells were further incubated for 30 min at 370C.  Following incubation, cells were 
washed with PBS, and formazan was extracted with 0.3 ml 100% isopropanol with continuous 
shaking at room temperature for 30 min. Aliquots (40 µl) of isopropanol extracts were diluted 
in isopropanol (160 µl) and absorbance was measured at 560 nm using a SpectraMax Plus 
Absorbance Microplate Reader (Molecular Devices, Sunnyvale, CA).  Each sample was 
measured in triplicate, and each experiment was repeated 3 independent times. 
Measurement of neutral lipids by ORO staining 
ORO staining was used to determine the cellular levels of neutral lipids such, as 
triglycerides and cholesterol esters, as previously described (Ramirez-Zacarias et al., 1992). 
Briefly, 0.35 g ORO was dissolved in 100 ml isopropanol and filtered. A working solution of 
ORO was prepared fresh by mixing 6 ml of ORO stock with 4 ml of water, and was filtered 
after incubating at room temperature for 20 min. Forty-eight hr after treatment, HepaRG cells 
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were washed in PBS and then fixed in PBS containing 10% formalaldehyde (w/v) for 1 hr.  
Fixed cells were washed three times with water and then incubated in isopropanol (60%) for 
10 minutes at room temperature.  Following incubation, isopropanol was removed and cells 
were allowed to dry completely, and then 1 mL of a filtered ORO solution was added to each 
well.  The cells were then incubated for 30 min at room temperature and rinsed four times with 
water. Nuclei were counterstained briefly using hematoxylin.  ORO-stained lipid vesicles were 
visualized at 200X using a phase-contrast microscope equipped with a digital camera 
(Olympus; Waltham, MA).  To quantify differences in neutral lipid accumulation, ORO was 
extracted from the cells by adding 100% isopropanol to each well and incubating at room 
temperature for 15 min with gentle agitation.  The absorbance of the extracted ORO was read 
at 510 nm. Experiment was repeated 3 independent times.   
Total RNA isolation and quantitative reverse transcription polymerase chain reaction 
(qRT-PCR)    
Following treatments, HepaRG cell cultures were harvested and total RNA was 
extracted and column purified using the Purelink RNA isolation kit (Ambion; Carlsbad, CA). 
Complementary DNA (cDNA) was synthesized using the High-Capacity cDNA Reverse 
Transcription Kit (Life Technologies; Grand Island, NY) following the manufacturer’s 
instructions.  Relative changes in gene expression were then assayed using either TaqMan or 
Power SYBR Green Master Mix and the StepOnePlus Real Time PCR system (Applied 
Biosystems; Foster City, CA).  Primer pairs were purchased from Integrated DNA 
Technologies (IDT; Coralville, IA) and their sequences are described in Appendix C. Tata-
binding protein (TBP) was used as the endogenous control (ID Hs.PT.58v.39858774; IDT). 
Relative fold-changes in mRNA levels were calculated using the comparative CT (ΔΔCT) 
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method (User bulletin no.2, Applied Biosystems, Foster City, CA) and all changes were 
normalized to the CT values for the endogenous control TBP. All assays were performed in 
duplicate, and each experiment was repeated three or more times.   
Measurement of hepatic fatty acid oxidation rate   
Differentiated HepaRG cells were cultured in 12-well plates at a density of 2.4 X 
104cells/cm2. Following treatment, fatty acid oxidation rates in intact cells were determined as 
described previously (Zhang et al., 2012), using [9,10-3H(N)]-OA as substrate and tritiated 
water as the measured end product of oxidation. Briefly, a complex of FF-BSA:OA (8mM OA) 
was prepared as described above. [9,10-3H(N)]-OA was included to achieve a final radiolabel 
concentration of 1µCi per mL in the treatment medium. The mixture was incubated for 30 min 
and then diluted in HepaRG treatment medium. 1 ml of medium containing the [3H]-OA was 
added to each well and the cells were incubated at 37 ºC for 3 hr, after which the medium was 
collected and protein precipitated by adding 100% trichloroacetic acid to a final concentration 
of 9% (v/v) and centrifugation. The supernatants were alkalinized by adding 6N NaOH and 
then were loaded onto columns containing 0.2 g/mL Dowex 1x2-400 resin (Sigma) diluted in 
water.  Tritiated water was eluted from the columns using 1.5 mL water into scintillation vials 
containing 10 mL Ultima-Flo™ M scintillation cocktail (PerkinElmer; (Waltham, MA) and 
radioactivity was measured using a Beckman-Coulter liquid scintillation counter (model 
LS3801; Indianapolis, IN).  Results were corrected for nonspecific radioactivity obtained from 
medium containing [3H]-OA that was not added to HepaRG cultures.  Experiments were 
conducted in quadruplicate, and repeated 3 independent times. 
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Measurement of hepatic lipid-metabolizing genes expression using customized PCR 
arrays  
96-well RT² Profiler™ PCR Array plates were purchased from Qiagen that were 
custom designed to contain primers for selected genes involved in human hepatic fatty acid 
synthesis, fatty acid oxidation (mitochondrial, peroxisomal), triglyceride biosynthesis, fatty 
acid transport, and cholesterol biosynthesis.  Prototypical target genes for assessing activation 
of nuclear receptors CAR (CYP2B6), FXR (short heterodimer partner, SHP), and PPARα 
(Plin2) were included as positive controls. Four housekeeping genes were also included for 
normalization. A complete list of the genes can be found in Appendix C.  Following treatment, 
HepaRG cells were harvested, and total RNA was isolated using the Purelink RNA isolation 
kit (Ambion).  cDNA was then prepared using the RT2 First Strand Kit (Qiagen) and PCR was 
performed using the RT² SYBR Green qPCR Master Mix according to manufacturer’s 
(Qiagen) recommendations using StepOnePlus Real Time PCR system. Fold changes in 
expression were analyzed using the web-based RT2 ProfilerTM PCR Array Data Analysis 
system (Qiagen), which is based on the ΔΔCt method, and raw data were normalized to 
housekeeping genes. Treatment-induced changes in mRNA levels were then normalized to the 
mRNA of the vehicle controls and these values were visualized as a heat map that was 
generated using GENE-E software v. 3.0.204 
(http://www.broadinstitute.org/cancer/software/GENE-E/index.html). Each experiment was 
conducted 2 independent times. 
Statistical analysis  
All results are presented as mean ± S.E.M. Significance testing was performed using 
GraphPad Prism version 6.00 for Mac OS X (GraphPad Software; San Diego, CA). As 
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appropriate, treatment groups were compared using one- or two-way analysis of variance with 
the Newman-Keuls correction for multiple comparisons or one-sample t-tests against the 
hypothetical value of 1. P <0.05 was considered statistically significant. 
2.3 Results  
2.3.1 HepaRG cell culture and differentiation. 
  Differentiated HepaRG cells have been previously shown to be a suitable in vitro 
system for studying hepatic lipid metabolic processes (Samanez et al., 2012; Brown et al., 
2013). We therefore used HepaRG cells as a model to evaluate the effects of farnesol on human 
hepatic lipid metabolism. The timeline for HepaRG culture expansion and differentiation is 
described in Figure 3.1A, and is detailed in the methods. HepaRG cell morphology during 
early (day 4) and late (day 14) growth phases, and during the differentiation phase (day 7) is 
shown in Figure 3.1B. As seen in the figure, differentiated HepaRG cells exist as a mixture of 
hepatocyte-like cells with bile canaliculus-like structures and colangiocyte-like cells in an 
approximate 1:1 ratio. 
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Figure 2.1 
 A 
 
B 
 
Figure 2.1 HepaRG cell culture and differentiation (A) Timeline of HepaRG cell culture 
and differentiation.  (B) Undifferentiated HepaRG cells in culture at day 4 and day 14, and 
differentiated HepaRG cells at day 7 after being cultured in differentiation medium containing 
2% DMSO.  
2.3.2 OA treatment induces accumulation of neutral lipids in differentiated HepaRG cells.  
 Differentiated HepaRG cells were exposed to increasing concentrations of OA (0.33, 
0.66 and 1mM), a known inducer of steatosis in human hepatic cells, including HepaRG cells 
(Ricchi et al., 2009; Anthérieu et al., 2011), for 48 hours. Oil Red O staining revealed a 
concentration-dependent increase of intracytoplasmic lipid droplets (stained in red) in response 
to OA treatment (Figure 2.2A). Quantification of the staining showed that absorbance was 
significantly increased by 1.3-, 1.7- and 1.9- fold at 0.33, 0.66 and 1mM OA, respectively, 
compared to the vehicle control (Figure 2.2B).   
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Figure 2.2                                                                   
    
 
Figure 2.2 Determination of neutral lipid accumulation by Oil Red O (ORO) staining in 
OA-overloaded HepaRG cells.  Differentiated HepaRG cells were incubated for 48 hr in 
HepaRG treatment medium-2, either alone (CON; untreated) or containing FF-BSA +EtOH 
(0.1%) (FF-BSA; vehicle control), either alone or complexed with 0.33mM, 0.66mM, or 1mM 
OA. Treatments were replaced once after 24 hours.  (A) ORO was used to stain the neutral 
lipids (triglycerides and cholesterol esters) and cells were photographed with a phase-contrast 
microscope at 200X magnification. The lipids are stained in red. (B) Quantification of ORO 
staining: ORO was extracted the cells in 100% isopropanol and the absorbance was measured 
at 510nM. Each bar is the mean ± SEM, n= 4. *, ** Significantly different than the vehicle 
control (FF-BSA), *P < 0.01, **P<0.001. 
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2.3.3 Optimization of FF- concentration for farnesol treatment in HepaRG cells. 
Given the hydrophobic nature of farnesol, FF-BSA was used as a carrier to facilitate 
uptake of farnesol into the HepaRG cells. For this purpose, we first determined the optimal 
concentration range for preparing FF-BSA and farnesol complex. Previous study in our lab has 
shown that farnesol can increase the expression of CYP2B1 gene in primary rat hepatocytes. 
We therefore measured the mRNA levels of the CYP2B6 gene, which is a human homologue 
of CYP2B1, as a reporter of farnesol’s effects on HepaRG cells. As shown in the Figure 2.3, 
treatment with increasing concentration of FF-BSA (0.03-0.3%) had no effects on the 
expression of CYP2B6 in HepaRG cells.  Further, treatment with 100µM farnesol complexed 
to FF-BSA increased the expression of CYP2B6 to similar levels for all concentrations of FF-
BSA used. Based on these data, farnesol was complexed with FF-BSA so that the final FF-
BSA concentration was 0.07% in the treatment media, which is same to that for media 
containing the FF-BSA: OA complex.  
2.3.4 Selection of optimal dose and treatment time for farnesol treatment in HepaRG cells.  
  Next, we treated HepaRG cells with 100µM farnesol for 24, 48 and 72 hr in order to 
determine an optimal culture time. Again, using the CYP2B6 gene as a reporter for farnesol 
treatment, we measured the changes in its mRNA levels in response to farnesol exposure. 
Compared to the FF-BSA (vehicle) control, farnesol had no effect on the expression levels of 
CYP2B6 gene at 24 hr (Figure 2.4A).  However, it increased the CYP2B6 mRNA levels at 32 
and 48 hr. In order to determine an optimal dose of farnesol, we treated HepaRG cells with 
increasing concentrations of farnesol (50, 100, and 300µM) for 48 hr (Figure 2.4B) and 
measured the mRNA levels of the CYP2B6 gene. Farnesol treatment resulted in concentration-
dependent increase in the CYP2B6 mRNA levels for 50 and 100µM concentrations, where as 
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the levels went down at 300µM. Based on our observations, we selected 100µM of farnesol as 
our optimal dose and 48 hr as our optimal culture time for future experiments. 
   
Figure 2.3  
 
 
Figure 2.3 Optimization of FF-BSA treatment in HepaRG cells. Differentiated HepaRG 
cells were cultured for 48 hr in HepaRG treatment medium-2 alone or containing the increasing 
concentrations of FF-BSA (0.03, 0.05, 0.1, 0.3%) either alone or in combination with farnesol 
(FOH, 100µM). Treatments were replaced once after 24 hours.  48 hr after treatment, cells 
were harvested for RNA isolation and cDNA synthesis, and mRNA levels of CYP2B6 was 
quantified by qRT-PCR, as described in Methods. Each bar represents the normalized mRNA 
values from a single experiment. 
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Figure 2.4
 
Figure 2.4 Dose- and time-dependent effect of farnesol on CYP2B6 gene expression in 
HepaRG cells. (A) Differentiated HepaRG cells were cultured in HepaRG treatment medium-
2 alone (UN; untreated) or containing either FF-BSA+ EtOH (0.1%) (FF-BSA; vehicle control) 
or farnesol (FOH; 100µM) for 24, 32 or 48 hr. (B) Differentiated HepaRG cells were cultured 
in HepaRG treatment medium-2 alone (UN; untreated) or containing either FF-BSA+ EtOH 
(0.1%) (FF-BSA; vehicle control) or farnesol (FOH; 50, 100, or 300 µM) for 48 hr. (A) and 
(B) Following treatments treatment, cells were harvested for RNA isolation and cDNA 
synthesis, and mRNA levels of CYP2B6 was quantified by qRT-PCR, as described in 
Methods. Each bar represents the normalized mRNA values from a single experiment. 
 
2.3.5 Farnesol has no toxic effects on differentiated HepaRG cell cultures.  
 In order to evaluate whether farnesol caused any cytotoxicity in HepaRG cultures, 
differentiated HepaRG cells were exposed to increasing concentrations of farnesol (10, 30, 
100, 300 and 1000µM) for 24 or 48 hr, and cell viability was measured by the MTT assay. 
Farnesol treatment had no effect on MTT absorbance at any of the concentrations or treatment 
times that were tested (Figure 2.5). Also, no changes in cellular morphology were noted when 
the cells were observed under phase-contrast microscopy (data not shown). 
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Figure 2.5 
 
Figure 2.5 Determination cell viability in farnesol-treated HepaRG cells.  Differentiated 
HepaRG cells were cultured for either 24 or 48 hr in HepaRG treatment medium-2 containing 
either FF-BSA+ EtOH (0.1%) (FF-BSA; vehicle control), alone or complexed with 10µM, 
30µM, 100µM, 300µM or 1000µM farnesol (FOH). Cells viability was determined by the MTT 
assay, as described in Methods. Each bar represents the mean MTT absorbance ± S.E.M of 
three independent experiments normalized to the FF-BSA group (n=3). 
2.3.6 Farnesol suppresses OA-induced lipid accumulation in HepaRG cells.  
 To determine the effect of farnesol on intracellular TGs accumulation in OA- 
overloaded HepaRG cells, differentiated HepaRG cells were pre-incubated with either FF-
BSA (0.7%) or 0.66mM OA (complexed with 0.7% FF-BSA) for 24 hr followed by treatment 
with either vehicle control (Ethanol; 0.1%) or farnesol (100µM) in the absence or presence of 
OA for another 48 hr, and intracellular TG levels were measured. Farnesol treatment had no 
effects on the TG levels under control conditions. Exposure to OA increased the amount of 
intracellular TG levels by 7.7–fold in HepaRG cells when compared to FF-BSA-treated 
controls (Figure 2.6). This OA-induced increase in TG levels was suppressed significantly by 
24.4% when HepaRG cells were co-treated with 100µM farnesol.  
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Figure 2.6 
  
Figure 2.6 Effect of farnesol treatment on intrahepatic TG levels in steatotic HepaRG 
cells. Differentiated HepaRG cells were cultured for 24 hr in HepaRG treatment medium-2 
containing FFA-BSA + EtOH (0.1%) or 0.66 mM oleic acid (OA) for 24 hrs. Thereafter, cells 
were incubated for 48 hr in pre-treatment medium (i.e., with FFA-BSA or OA) containing 
either EtOH (0.1%) (vehicle control) or farnesol (FOH; 100µM). Cells were then harvested for 
TG measurement, as described in Methods. The amount of TGs was normalized to protein for 
each sample. Each bar is the mean ± SEM from three independent experiments (n=3). ***, 
Significantly different from FF-BSA: EtOH group, p<0.001. #, Significantly different from 
OA:EtOH group, p<0.05. 
 
2.3.7 Farnesol activates lipid-sensing nuclear receptors in HepaRG cells.  
  Since farnesol has been previously shown to mediate physiological responses, 
including lipid metabolism, through activation of PPARα, CAR and FXR, we hypothesized 
that one or more of these receptors could be involved in the observed farnesol-mediated 
reduction of TG in our hepatic steatosis model. For this, we first determined whether farnesol 
affected the activity of CAR, PPARα or FXR in HepaRG cells. Differentiated HepaRG cells 
were treated with either farnesol or known agonists for the individual nuclear receptors for 48 
hr, and expression levels of their respective target genes were measured by qRT-PCR (Figure 
2.7). We found that treatment with the CAR agonist CITCO (0.1µM), PPARα agonist GW7647 
(10µM) and the FXR agonist GW4064 (1µM) significantly increased the expression of their 
target genes CYP2B6 (CAR), perilipin 2 (PLIN2, PPARα) and short heterodimer partner (SHP, 
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FXR) by ~4-fold, ~5-fold and ~3-fold, respectively, compared to vehicle-treated control. 
Treatment with farnesol (100µM) significantly increased the expression of CYP2B6 by 2-fold 
and PLIN2 by 1.7-fold. However, farnesol treatment had no effect on expression of SHP. These 
findings indicate that farnesol can modulate activity of CAR and PPARα, but not FXR, at least 
under the current experimental conditions in HepaRG cells. 
 
Figure 2.7  
 
Figure 2.7 Effect of farnesol on the activity of nuclear receptors in HepaRG cells. 
Differentiated HepaRG cells were cultured in HepaRG treatment medium-2 containing either 
FF-BSA+ EtOH (0.1%) (FF-BSA; vehicle control), farnesol (FOH, 100µM), DMSO (0.1%) or 
the respective agonist for each nuclear receptor: CITCO (CAR; 0.1µM), GW7647 (PPARα; 
10µM) or GW4064 (FXR; 1µM). Treatments were replaced once after 24 hours.  48 hr after 
treatment, cells were harvested for RNA isolation and cDNA synthesis, and mRNA levels of 
CYP2B6, PLIN2 and SHP were quantified by qRT-PCR, as described in Methods. Each bar 
represents the mean ± S.E.M. of normalized mRNA values from three (PLIN2) to four 
(CYP2B6, SHP) independent experiments. *, ** Significantly different from the vehicle 
control (BSA), * P<0.05; ** P<0.01.  
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2.3.8 Farnesol changes the expression of hepatic lipid metabolizing enzymes in steatotic 
HepaRG cells.  
 In order to investigate mechanisms behind farnesol-mediated suppression of lipid 
accumulation in OA-overloaded HepaRG cells, we designed a customized PCR array and 
measured changes in the expression of genes involved in various lipid-metabolizing pathways 
in human liver, which included genes responsible for fatty acid synthesis, fatty acid oxidation, 
TG biosynthesis, fatty acid uptake and transport, lipoprotein secretion and cholesterol 
biosynthesis. The list of genes is shown in Appendix A. HepaRG cells were treated either with 
farnesol, OA, OA and farnesol, or agonists for PPARα, CAR and FXR. mRNA levels for all 
genes were measured. The results are represented as a heat map in Figure 2.8 and are presented 
in detail in the Appendix B.  
 Our data shows that activation of CAR in HepaRG cells by CITCO resulted in 
upregulation in the mRNA levels of CYP2B6, ELOVL3, ACADS, ACOT12, PPARα, 
AGPAT2, FASN and ACOT1 and suppressed the expression of NR0B2, CD36, CYP4A11, 
and ACOT6.   Similarly, activation of FXR by GW4064 upregulated expressions of SHP, 
PPARG, APOA5, ACSL5, AGPAT2, ELOVL3, ACADS, PPARA, AGPAT9, FASN, ACSL3, 
AGPAT6, AGPAT1, while genes, such as NR1H4, DGAT2, FABP1, SCD, ACOT6, CYP2B6, 
DGAT1, LIPC, CYP4A11, ACOX2, CYP2E1, and PCK1were downregulated. A large number 
of genes regulating hepatic fatty acid oxidation, and fatty acid uptake and transport were 
upregulated by PPARα activation, which included ACAA1, CD36, FABP1, PLIN2, ACADS, 
PCK1, HADHB, ACAA2, SLC27A2, CPT1A, APOA5, AGPAT2, HADHA, CYP4A11, 
ACSL5, ACOT12, ACSL4, ACADM, ACOT1, CPT2, ACADVL, ACACB, ACSL3, DHDDS, 
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SCD, ACOX1, AGPAT9, LIPC, EHHADH, SREBF1, PPARG, and ACOX2. Among the 
genes studies, the only gene downregulated by activation of PPARα was SHP.   
 Farnesol treatment increased the expression of CYP2B6, FABP1, ACOX2, SLC27A2, 
ACOT12, ELOVL4, PPARG, ELOVL3, FDFT1, PDSS1, APOA5, LIPC, ACAA2, ACAT2, 
ACAT1, and PLIN2, majority of which were also upregulated by PPARα activation. Also, 
farnesol reduced the mRNA levels of AGPAT2, ACACB, CYP2E1, PCK1, SLC27A1, and 
SREBF1. Incubation in OA increased the expression of APOA5, PCK1, ACOT12, HADHB, 
CD36, PLIN2, AGPAT2, AGPAT9, ACADS, ACAA2, ELOVL3 and CYP2E1 while 
expression of ACOX2, SHP, CAR, SCD5, GPAT2, SREBF1, CYP2B6, IL6, and SCD were 
suppressed. Co-treatment of farnesol in OA-overloaded HepaRG cells upregulated expression 
of APOA5, ACOT12, PCK1, ELOVL3, ACADS, CYP2B6, CYP2E1, PLIN2, ACAA2, 
CPT1A, PPARα, ACSL5, HADHB, ELOVL6, AGPAT6, HMGCR, ACSL4, HADHA, 
ACOX1 and ACADM while expression of RABGGTA, AGPAT1, SCD, GPAT2 and SHP 
were downregulated.  
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Figure 2.8 
 
 
 
Figure 2.8 Effect of farnesol on hepatic lipid-metabolizing gene expression in HepaRG 
cells.  Differentiated HepaRG cells were cultured in HepaRG treatment medium-2 containing 
either vehicle control (FF-BSA) or OA (0.66mM) for 24 hr. Thereafter, FF-BSA pre-treated 
group was treated with either the vehicle control (FF-BSA+EtOH (0.1%) or farnesol (100µM, 
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FOH) for 48 hr. The OA pre-treated group was incubated in medium containing OA in 
combination with one of the following: FOH (100µM), DMSO (0.1%), CITCO (0.1µM), 
GW7647 (10µM) or GW4064 (1µM) for 48 hr. Treatments were replaced once after 24 hours. 
Cells were then harvested for RNA isolation and cDNA synthesis, and mRNA levels of 85 
lipid-metabolizing genes, positive controls for nuclear receptors and internal controls were 
measured using the custom RT2 ProfilerTM PCR Array kit, as described in Methods.  Fold 
changes in expression were analyzed using the web-based RT2 ProfilerTM PCR Array Data 
Analysis system (Qiagen) that is based on the ΔΔCt method, and raw data were normalized to 
housekeeping genes. Treatment-induced changes in gene expression were then normalized to 
the expression values of the vehicle control and presented as a heat map that was generated 
using GENE-E software. The microarray experiment was conducted 2 independent times.  
 
2.3.9 Farnesol upregulates expression of fatty acid oxidation genes in steatotic HepaRG 
cells. 
 We validated the results from our microarray experiments by qRT-PCR using self-
designed primers, as described in Appendix C. Since fatty acid oxidation was the major 
pathway modulated by farnesol, we measured the mRNA levels of mitochondrial and 
peroxisomal β-oxidation genes in HepaRG cells that were treated similarly to the array 
experiments. Under control conditions, farnesol had no significant effects on the expression of 
mitochondrial β-oxidation genes except for hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA             
thiolase/enoyl-CoA hydratase (trifunctional protein), alpha subunit (HADHA) (Figure 2.9). 
OA treatment significantly increased expression of HADHA (~1.5-fold), hydroxyacyl-CoA 
dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase (trifunctional protein), beta 
subunit (HADHB, ~1.5-fold), and acetyl-coenzyme A acyltransferase 2 (ACAA2, ~1.3-fold). 
Co-treatment with farnesol further increased the expression of HADHA (~1.2-fold), HADHB 
(~1.2-fold), and ACAA2 (~1.3-fold), when compared to the OA-only treated samples. In 
contrast, neither farnesol nor OA had any effect on the expression of peroxisomal β-oxidation 
genes except for ACOX2, which was suppressed by both farnesol (~1.2-fold) and OA (~1.3-
fold). Additionally, expression of the cytosolic thioesterase, Acyl-CoA thioesterase 12 
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(ACOT12) increased by ~1.5-fold over control in response to farnesol treatment and ~1.8-fold 
by OA treatment. Co-treatment with farnesol further increased the OA-mediated increase in 
ACOT12 expression by ~1.5-fold.    
Figure 2.9 
 
Figure 2.9 Effect of farnesol on lipid-metabolizing gene expression in OA-overloaded 
HepaRG cells. Differentiated HepaRG cells were cultured in HepaRG treatment medium-2 
containing either vehicle control (FF-BSA) or OA (0.66mM) for 24 hr. Thereafter, the FF-
BSA pretreated group was treated with either FF-BSA+EtOH (0.1%) (FF-BSA; vehicle 
control) or farnesol (FOH, 100µM) for 48 hr. The OA pretreated group was treated either with 
FF-BSA+EtOH (0.1%) (OA) or farnesol (OA+FOH) in media containing OA (0.66 mM). 
Treatments were replaced once after 24 hours. Cells were then harvested for RNA isolation 
and cDNA synthesis, and mRNA levels of genes regulating fatty acid oxidation were 
quantified by qRT-PCR, as described in Methods. Each bar represents the mean ± S.E.M. of 
normalized mRNA levels from three independent experiments (n=3) and are normalized to the 
FF-BSA treated control. *, ** Significantly different from vehicle control (FF-BSA); *, 
P<0.05; **, P<0.01.  
 
HADHA HADHB ACAA2 EHHADH ACOX1 ACOX2 ACOT12
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
R
el
at
iv
e 
m
R
N
A
 le
ve
ls
(F
ol
d 
ov
er
 F
F-
B
SA
 c
on
tr
ol
)
EtOH
FOH
OA
OA+ FOH
*
*
**
**
** **
*
** *
**
**
**
A
Mitochondrial Peroxisomal Cytosolic
	   45	  
	  
2.3.10 Farnesol treatment increases fatty acid oxidation in OA-overloaded HepaRG cells. 
 We determined the effect of farnesol on overall fatty acid oxidation rate in OA-treated 
HepaRG cells using oleic acid radiolabelled with tritium (3H) as the precursor and measured 
the amount of titrated water, which is the end product of lipid oxidation (Figure 2.10). In OA-
overloaded HepaRG cells, farnesol significantly increased total fatty acid oxidation rate by 
~1.5-fold. The oxidation rate was also increased by treatment with 10µM GW7647 (a known 
PPARα agonist and positive control for fatty acid oxidation).  Taken together, our findings 
indicate that under steatogenic conditions, farnesol increases the hepatic fatty acid oxidation 
rate by regulating the expression of mitochondrial and microsomal oxidation enzymes but not 
the peroxisomal oxidation.  
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Figure 2.10  
  
Figure 2.10 Effect of farnesol on fatty acid oxidation rate in OA-overloaded HepaRG 
cells. Differentiated HepaRG cells were pretreated with 0.66mM OA in HepaRG treatment 
medium-2 for 24 hr. Cells were then treated with either the FF-BSA+EtOH (0.1%) (FF-BSA; 
vehicle control) or farnesol (100µM; FOH), DMSO (0.1%), or GW7647 (10µM; positive 
control for fatty acid oxidation activation) for 48 hr. Treatments were replaced once after 24 
hours. Following treatments, cells were prepared to measure the fatty acid oxidation rate as 
described in Methods. Values were normalized to protein and all samples were normalized to 
the EtOH+BSA treated controls. Each bar represents the mean ± S.E.M. of normalized values 
from three independent experiments (n=3). *, Significantly different from untreated (UT) 
group; P<0.01. #, Significantly different from DMSO group; P<0.05. 
 
2.3.11 Farnesol modulates expression of hepatic enzymes in OA-treated HepaRG cells. 
 Farnesol also modulated the expression of various other metabolic enzymes as shown 
in Figure 2.11. Farnesol suppressed expression of SREBP1c (~ 1.2-fold), and increased 
expression of APOA5 (~ 1.3-fold) and ACOT12 (~ 1.5-fold) under control conditions. OA 
treatment suppressed expression of SREBP1c (~ 1.4-fold) and SCD (~ 2.8-fold), and increased 
the expression of APOA5 (~ 2.5-fold) and PCK1 (~ 2.4-fold). Co-treatment with farnesol 
further increased OA-mediated induction of APOA5 (~ 1.6-fold), and reversed the OA-
mediated suppression of SCD (~ 1.4-fold). However, farnesol did not change the mRNA levels 
of PCK1 in both control and OA-treated conditions. 
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Figure 2.11  
 
Figure 2.11 Effect of farnesol on hepatic enzymes in OA-overloaded HepaRG cells. 
Differentiated HepaRG cells were pretreated for 24 hr in HepaRG treatment-2 containing FF-
BSA, either alone (BSA) or complexed with 0.66mM OA. The cells were then incubated for 
48 hr in pre-incubation medium (i.e., BSA or OA) containing either 0.1% EtOH or 100µM 
farnesol (FOH). Treatments were replaced once after 24 hours. Cells were then harvested for 
RNA isolation and cDNA synthesis, and mRNA levels of genes were quantified by qRT-PCR, 
as described in Methods. Each bar represents the mean ± S.E.M. of normalized mRNA levels 
from three independent experiments (n=3) and are normalized to the EtOH-BSA treated 
control. *, Significantly different from EtOH:BSA group, P<0.05. #, Significantly different 
from EtOH:OA group, P<0.05. 
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2.3.12 Farnesol modulates expression hepatic drug-metabolizing enzymes in OA-overloaded 
HepaRG cells. 
 We also measured the changes in the expression of various cytochromes P450, which 
are primarily involved in drug metabolism and microsomal oxidation (Zanger and Schwab, 
2013), response to farnesol treatment in OA-overloaded HepaRG cells. As shown in Figure 
2.12, OA significantly downregulated the mRNA levels of CYP1A2 (~ 1.8-fold), CYP2B6 (~ 
2.6-fold) and CYP3A4 (~1.2-fold) while it increased the levels of CYP2E1 (~1.3-fold). 
Farnesol significantly upregulated CYP3A4 (~1.9-fold) and CYP2B6 (~2.6-fold) mRNA 
levels in control HepaRG cells, and reversed the OA-mediated suppression of CYP1A2, 
CYP3A4 and CYP2B6 in OA-overloaded cells (Figure 2.12). Also, farnesol suppressed 
mRNA levels of CYP2E1 in control cells (~ 1.5-fold) and reversed its OA-mediated 
upregulation in OA-overloaded HepaRG cells. 
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Figure 2.12 
 
Figure 2.12 Effect of farnesol on hepatic drug-metabolizing enzymes in OA-overloaded 
HepaRG cells. Differentiated HepaRG cells were cultured in HepaRG treatment medium-2 
containing either vehicle control (FF-BSA) or OA (0.66mM) for 24 hr. Thereafter, FF-BSA 
pretreated group was treated with either the vehicle control (FF-BSA+EtOH (0.1%); FF-BSA) 
or FOH (100 µM) for 48 hr. The OA pretreated group was treated in the same way in media 
containing OA (0.66 mM). Treatments were replaced once after 24 hours. Cells were then 
harvested for RNA isolation and cDNA synthesis, and mRNA levels of genes involved in drug 
metabolism were quantified by qRT-PCR, as described in Methods. Each bar represents the 
mean ± S.E.M. of normalized mRNA levels from three independent experiments (n=3) and are 
normalized to the FF-BSA treated control. *, ** Significantly different from vehicle control 
(FF-BSA); *, P<0.05; **, P<0.01.  
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2..3.13 Farnesol changes expression of mitochondrial β-oxidation genes through PPARα.  
 Next, we determined whether the observed changes in mitochondrial β-oxidation gene 
expression involved PPARα as suggested by our customized array data. Differentiated 
HepaRG cells were treated with GW7647 (10µM) in control and OA-treated HepaRG cells 
and changes in gene expression were measured by qRT-PCR. In control HepaRG cells, PPARα 
activation significantly induced expression of HADHA (~2-fold), HADHB (~1.6-fold) and 
ACAA2 (~1.8-fold), except for ACOT12 (Figure 2.13). Treatment with OA also upregulated 
HADHA (~1.4-fold), HADHB (~1.6-fold), ACOT12 (~1.9-fold) and ACAA2 (~1.4-fold) and 
this OA-mediated induction in HADHA, HADNB and ACAA2 was increased further by ~1.5-
fold, ~1.4-fold and ~1.3-fold by GW7647 co-treatment, except for ACOT12. This suggests 
that except for ACOT12, all three genes are regulated by PPARα and that PPAR target genes 
are upregulated by OA treatment in HepaRG cells. Next, OA overloaded HepaRG cells were 
treated with farnesol in the presence or absence of the PPARα antagonist GW6471 (10µM) for 
48 hr and expression of HADHA, HADHB and ACAA2 was measured using qRT-PCR 
(Figure 2.14). Validation of PPARα antagonism by GW6471 treatment is shown in Figure 
2.14A where co-treatment with GW6471 dose-dependently suppressed GW7647-mediated 
induction of FABP1, which is a PPARα target gene. GW6471 treatment significantly 
antagonized the farnesol-mediated induction of HADHA, HADHB and ACAA2 expression 
(Figure 2.14B) suggesting that under steatogenic conditions, farnesol increases the expression 
of mitochondrial β-oxidation genes through activation of PPARα in HepaRG cells. 
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Figure 2.13  
  
Figure 2.13 Effect of PPARα activation on mitochondrial β-oxidation genes in HepaRG 
cells.  Differentiated HepaRG cells were cultured in HepaRG treatment medium-2 containing 
either the vehicle control DMSO (0.1%) or the PPARα agonist GW7647 (10µM) in control or 
OA (0.66mM)-treated HepaRG cells for 48 hr. Treatments were replaced once after 24 hours. 
Cells were then harvested for RNA isolation and cDNA synthesis, and mRNA levels of 
mitochondrial β-oxidation genes were quantified by qRT-PCR, as described in Methods. Each 
bar represents the mean ± S.E.M. of mRNA levels normalized to the DMSO control from three 
(HADHB, ACAA2; n=3) or four (HADHA, ACOT12; n=4) independent experiments. 
*,**,*** Significantly different from vehicle control (DMSO); *, P<0.05; **, P<0.01, ***, 
P<0.001. #, ## Significantly different from OA treated groups. #, P<0.05; ##, P<0.01. 
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Figure 2.14  
 
 
 
 
 
 
  
Figure 2.14 Effect of PPARα antagonist on farnesol-mediated upregulation of 
mitochondrial β-oxidation genes in HepaRG cells.  A) Validation of PPARα antagonism 
by GW6471. Differentiated HepaRG cells were treated with either vehicle control (DMSO; 
0.1%), the PPAR agonist GW7674 (10µM) alone or in combination with the PPARα antagonist 
GW6471 (1 or 10 µM), or GW6471 (1 or 10 µM) alone for 48 hrs.  Treatments were replaced 
once after 24 hours. Cells were then harvested for RNA isolation and cDNA synthesis, and 
mRNA levels of FABP1 were quantified by qRT-PCR, as described in Methods. Each bar 
represents the mean mRNA levels normalized to the DMSO control from two independent 
experiments. B) Effect of GW6471 on farnesol-mediated upregulation of mitochondrial β-
oxidation genes. Differentiated HepaRG cells were pre-treated with OA (0.66mM) for 24 hr 
in HepaRG treatment medium-2 followed by a 48 treatment with medium containing OA 
(0.66mM) either alone or in combination with farnesol (100µM; FOH), FOH and the PPAR 
antagonist GW6471 (10µM), or GW6471 alone. Treatments were replaced once after 24 hours. 
Cells were then harvested for RNA isolation and cDNA synthesis, and mRNA levels of 
mitochondrial β-oxidation genes were quantified by qRT-PCR, as described in Methods. Each 
bar represents the mean ± S.E.M. of mRNA levels normalized to the DMSO control from three 
(HADHA, ACAA2; n=3) or four (HADHB; n=4) independent experiments. **, *** 
Significantly different from OA only treated group; **, P<0.01; ***, P<0.001. #, Significantly 
different from OA + FOH treated groups. ###, P<0.001. 
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2.4 Discussion 
 The pathogenesis of NAFLD involves dysregulation of lipid metabolic pathways that 
are regulated by nuclear receptors, such as the PPARs (Sambasiva Rao and Reddy, 2004; 
Tailleux et al., 2012), FXR (Sinal et al., 2000), CAR (Yamazaki et al., 2007), pregnane X 
receptor (Sookoian et al., 2010), and liver X receptor (Ducheix et al., 2013). Therefore, 
pharmacological manipulations of these nuclear receptors are regarded as potential approaches 
for NAFLD treatment (López-Velázquez et al., 2012; Machado and Cortez-Pinto, 2014). 
Several synthetic nuclear receptor activators, including fibrates (PPARα), thiazolidinediones 
(PPARγ), GW501516 and MBX-8025 (PPARβ/δ) (Tailleux et al., 2012), and obeticholic acid 
(FXR) (Adorini et al., 2012) have been tested in clinical trials for treatment of NAFLD. In 
addition to synthetic agonists, these nuclear receptors are also targeted by several classes of 
endogenous compounds, including bile salts (FXR) (Wang et al., 1999) and lipoproteins, 
eicosanoids, fatty acids, and prostaglandins (PPARs) (Kliewer et al., 1997; Schupp and Lazar, 
2010). Here, we have studied farnesol, an endogenous isoprenoid that suppresses TG 
accumulation in the hepatocytes of high-fat diet-fed mice (Goto et al., 2011) and the serum of 
Sprague–Dawley rats (Duncan and Archer, 2008) through activation of PPARα, PPARγ, 
and/or FXR (Forman et al., 1995; Takahashi et al., 2002; Hiyoshi et al., 2003; Goto et al., 
2011). However, extrapolation of farnesol’s effects on lipid metabolism from rodents to human 
is complicated by interspecies differences in the activities and functions of these receptors; 
particularly for PPARα, which in known to regulate diverse sets of lipid-metabolizing genes 
in mouse and human hepatocytes (Rakhshandehroo et al., 2009), possibly due to differences 
in ligand affinity, the PPREs in the target genes, and the transcriptional co-regulators that are 
recruited (Ammerschlaeger et al., 2004; Gonzalez and Shah, 2008; Yang et al., 2008). These 
disparities may explain why pharmacological modulation of PPARα, while preventing 
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steatosis in preclinical animal studies, has not proven as effective for treatment of steatosis in 
clinical trials (Tailleux et al., 2012). In view of the above-described differences, we evaluated 
whether farnesol treatment could suppress TG accumulation under steatogenic conditions in 
human hepatic cells, using OA-treated HepaRG cells as our model. Farnesol treatment lowered 
intrahepatic TGs by nearly 25% in OA-loaded HepaRG cells, suggesting that farnesol can 
potentially suppress steatosis in human hepatocytes.  
 Farnesol-mediated activation of human PPARα has not yet been clearly defined. In 
transfection assays conducted in CV1 cells, farnesol treatment activated a chimeric receptor 
containing the human PPARα ligand-binding domain and GAL4 DNA-binding domain as well 
as the full-length receptor (Takahashi et al., 2002). Also, in the same study, HepG2 cells 
engineered to overexpress human PPARα, farnesol increased expression of PPARα target 
genes. In our initial studies, we found that farnesol treatment increased expression of the 
PPARα target gene PLIN2, showing that farnesol can activate endogenous PPARα in HepaRG 
cells. Farnesol treatment also increased expression of CYP2B6, indicating that farnesol can 
also modulate human CAR-mediated responses. Farnesol has been previously shown to 
activate FXR in cultured rat hepatocytes (Goto et al., 2011). However, farnesol treatment did 
not change expression of the FXR target gene SHP in our study even though FXR was robustly 
activated by the positive control agonist GW4064, which might be attributable to farnesol 
being a relatively weak FXR agonist (Forman et al., 1995) or to species differences in FXR 
activation. 
 Farnesol upregulates genes involved in fatty acid oxidation in cultured rat hepatocytes 
(Duncan and Archer, 2008) and the livers of high fat-fed mice (Goto et al., 2011). The results 
from our customized microarray and qRT-PCR analyses indicated that farnesol treatment of 
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OA-loaded HepaRG cells increased the expression of several genes that are responsible for 
hepatic lipid oxidation (i.e., HADHA, HADHB, ACAA2, and ACOT12), which translated to 
increased fatty acid oxidation. Farnesol treatment has also been reported to suppress expression 
of the lipogenic genes SREBP-1c and FAS in obese mice (Goto et al., 2011) and FAS but not 
SREBP-1c in cultured rat hepatocytes (Duncan and Archer, 2008). Our microarray data 
indicated that farnesol treatment suppressed the expression of SREBP-1c but not FAS in 
HepaRG cells, suggesting that farnesol-mediated regulation of hepatic lipid-metabolizing gene 
expression can differ across species.  
 OA-treated HepaRG cells are reported to show decreased expression of lipogenic genes 
and increased expression of genes regulating fatty acid oxidation and lipid droplet formation. 
(Anthérieu et al., 2011). Also, treatment of HepaRG cells with the fatty acid palmitate, either 
alone or in combination with OA in1:2 ratio changes the metabolic profile to one that resembles 
NAFLD, including abnormal mitochondrial metabolism, altered fatty acid oxidation, and 
development of insulin resistance (Brown et al., 2013). When these OA-loaded HepaRG cells 
are treated with PPARα or dual PPARα/γ agonists, TG accumulation is suppressed, which is 
accompanied by increases in fatty acid oxidation, upregulation of genes regulating fatty acid 
oxidation, and downregulation of lipogenic genes (Rogue et al., 2014), suggesting that 
activation of PPARs in OA-treated HepaRG cells can reverse steatosis. In the current study, 
farnesol treatment of control or OA-loaded HepaRG cells increased expression of several lipid-
metabolizing genes that were also upregulated by PPARα agonist (GW7647) treatment. 
GW7647 treatment of control and OA-loaded HepaRG cells increased expression of the 
mitochondrial β-oxidation proteins HAHDA, HADHB, and ACAA2, while the amount of 
ACOT12 mRNA was not changed. ACOT12 is a cytoplasmic enzyme that catalyzes the 
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hydrolysis of acetyl-CoA, and the enzyme’s activity is regulated by ADP/ATP levels 
(Swarbrick et al., 2014). ACOT12 in rats has a peroxisome proliferator responsive element 
(PPRE) motif in its promotor region, which is consistent with the observed increase in 
ACOT12 activity upon treatment with the PPARα agonist CPIB (clofibrate) in rats’ 
hepatocytes. However, in human ACOT12, the PPRE motif is found outside the putative 
promoter region in the introns and studies have suggested that human ACOT12   may not be 
responsive towards activation by PPAR activators, which is further validated by our findings. 
Finally, we found that farnesol-mediated upregulation of HADHA, HADHB and ACAA2 was 
attenuated by the PPARα antagonist GW6471 in OA-loaded HepaRG cells, demonstrating that 
farnesol’s effects on these mitochondrial β-oxidation genes are mediated thorough PPARα. 
  In our study, OA-treatment decreased the expression of CYP1A2, CYP2B6, and 
CYP3A4 and increased CYP2E1 expression. Changes in the expression of various P450s are 
routinely seen in the livers of NAFLD patients, resulting in altered drug metabolism (Merrell 
and Cherrington, 2011). CYP2E1 is also directly involved in NAFLD pathogenesis because of 
its role in lipid peroxidation that increases oxidative stress, one of the factors responsible for 
NAFLD progression (Chalasani et al., 2003). All of the OA-induced changes in P450 
expression were attenuated by farnesol co-treatment. Farnesol has been previously reported to 
modulate expression of rat P450s and to interact with mammalian P450s as a substrate and/or 
inhibitor. Specifically, farnesol has been shown to increase CYP2B mRNA levels in primary 
cultured rat hepatocytes (Kocarek and Mercer-Haines, 2002), induce several monooxygenase 
activities in rat liver (Horn et al., 2005),  inhibit monooxygenase activities in rabbit liver 
microsomes (Raner et al., 2002), and be a substrate for ω-hydroxylation by rabbit and human 
CYP2E1 (DeBarber, 2004 #248). Our findings suggest that farnesol can potentially normalize 
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fatty acid-induced changes in the hepatic expression of several human drug-metabolizing 
enzymes. 
 In conclusion, our results suggest that farnesol can exert potentially beneficial effects 
on human hepatic lipid and drug metabolism. Farnesol can reverse fatty acid-induced steatosis 
in human hepatic cells by increasing the expression of genes responsible for mitochondrial β-
oxidation, primarily through activation of the nuclear receptor PPARα. Farnesol’s ability to 
normalize expression of human P450s might be an effective approach to ameliorate altered 
metabolism of drugs during treatment of NAFLD, but this possibility requires further 
investigation. Additionally, farnesol has been shown to function as a dual human PPARα/γ 
activator (Takahashi et al., 2002). Although we did not include PPARγ in this study, since 
PPARα is the major PPAR that is expressed in human liver, it would be interesting to determine 
whether PPARγ contributes to any of farnesol’s effects using selective antagonists, such as 
GW9662 (Zhang et al., 2015). 
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CHAPTER 3: ROLE OF PHOSPHATIDIC ACID PHOSPHATASE DOMAIN 
CONTAINING 2 (PPAPDC2) IN SQUALESTATIN 1-MEDIATED ACTIVATION OF 
THE CONSTITUTIVE ANDROSTANE RECEPTOR IN PRIMARY CULTURED 
RAT HEPATOCYTES. 
Published: Pant A and Kocarek TA (2015) Role of Phosphatidic Acid Phosphatase Domain 
Containing 2 (PPAPDC2) In Squalestatin 1-Mediated Activation of the Constitutive 
Androstane Receptor in Primary Cultured Rat Hepatocytes. Drug Metab Dispos. 
3.1 Introduction 
  The mevalonate pathway comprises the first portion of the cholesterol biosynthetic 
pathway, and its rate-limiting enzyme, 3-hydroxy-3-methylglutarylcoenzyme A reductase 
(HMGCR), is the target of the statin class of cholesterol-lowering drugs. The mevalonate 
pathway is a highly conserved process whereby acetyl-CoA is converted to a series of 
progressively elongated isoprenoids that include the branch-point metabolite, farnesyl 
pyrophosphate (FPP, also known as farnesyl diphosphate). While FPP is normally converted 
mainly to squalene by squalene synthase in the first committed step of sterol biosynthesis, it is 
also metabolized to several non-sterol isoprenoids including ubiquinone (coenzyme Q), 
dolichol, dolichyl phosphate, heme O, heme A, and isopentenyl tRNA (Goldstein and Brown, 
1990). Also, FPP and its metabolite geranylgeranyl pyrophosphate (GGPP) are substrates for 
protein prenylation reactions, which are required for cellular signaling by small GTPases 
(Zhang and Casey, 1996). FPP and GGPP are also precursors to the isoprenols, farnesol and 
geranylgeraniol (Edwards and Ericsson, 1999). Under normal physiological conditions, little 
FPP is dephosphorylated to farnesol, but when squalene synthase is inhibited, FPP 
accumulates, leading to massive production of farnesol and its progressively oxidized 
metabolites (collectively known as farnesoids), farnesal, farnesoic acid, and a series of 
dicarboxylic acids that are excreted in urine (Bostedor et al., 1997; Vaidya et al., 1998).  
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 Our lab has previously reported that treatment of primary cultured rat hepatocytes with 
the squalene synthase inhibitor, squalestatin 1 (SQ1), increases CYP2B1 expression by causing 
accumulation of an endogenous isoprenoid(s) that activates the constitutive androstane 
receptor (CAR; NR1I3) (Kocarek and Mercer-Haines, 2002; Jackson and Kocarek, 2008). 
Additional evidence implied that this effect required the conversion of FPP to farnesol, since 
direct treatment with farnesol caused CYP2B induction in cultured rat hepatocytes (Kocarek 
and Mercer-Haines, 2002) and rat liver (Horn et al., 2005a). However, this possibility was not 
specifically addressed since the enzyme(s) responsible for converting FPP to farnesol was not 
known. Later, phosphatidic acid phosphatase domain containing 2 (PPAPDC2) was identified 
as a lipid phosphate phosphohydrolase that could convert presqualene diphosphate to 
presqualene monophosphate (Fukunaga et al., 2006). Subsequently PPAPDC2 was shown to 
hydrolyze FPP and GGPP preferentially over several other phospholipid substrates in vitro and 
to deplete FPP levels when overexpressed in cells (Miriyala et al., 2010). These data suggested 
that PPAPDC2 could be an important component of the pathway for synthesis of isoprenols. 
Therefore, the objective of the current investigation was to determine the impact of PPAPDC2 
activity on SQ1-mediated activation of CAR in primary cultured rat hepatocytes. 
3.2 Materials and methods 
Materials 
SQ1 was a gift from Bristol-Myers Squibb Co. (Stamford, CT) and pravastatin from 
GlaxoSmithKline (Research Triangle Park, NC). Phenobarbital (PB) was purchased from 
Sigma-Aldrich (St. Louis, MO). Matrigel was purchased from Corning Life Sciences 
(Tewksbury, MA), PureCol from Advanced BioMatrix (San Diego, CA), and recombinant 
human insulin (Novolin R) from Novo Nordisk Pharmaceuticals, Inc. (Princeton, NJ). 
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Williams’ Medium E and Lipofectamine 2000 reagent were purchased from Invitrogen (Life 
Technologies; Grand Island, NY). SYBR Green PCR master mix was purchased from Applied 
Biosystems (Foster City, CA). Additional materials were obtained from the sources indicated 
below. 
Primary culture of rat hepatocytes  
Adult male Sprague-Dawley rats (200–250 g) were purchased from Harlan Sprague-
Dawley (Indianapolis, IN) and maintained in an Association for Assessment and Accreditation 
of Laboratory Animal Care-approved animal facility with free access to food and water for one 
week. Hepatocytes were isolated by two-step collagenase perfusion as described previously 
(Kocarek and Reddy, 1996). Freshly isolated hepatocytes were plated onto PureCol-coated 
plates at a density of 1.6 million hepatocytes per well for 6-well plates (for RNA isolation) or 
0.6 million hepatocytes per well for 12-well plates (for transfection experiments) and 
maintained at 37°C under a humidified atmosphere of 95% air/5% CO2 in Williams' Medium 
E supplemented with 0.25 U/ml insulin, 0.1 µM triamcinolone acetonide, 100 U/ml penicillin, 
and 100 µg/ml streptomycin. Culture medium was renewed every 24 hr and drug treatments 
were begun 48 hr after plating as described in the individual figure legends. Drugs were 
prepared as 1000X stock solutions in sterile water. 
PPAPDC2 overexpression by transient transfection in primary cultured rat hepatocytes 
A CAR-responsive firefly luciferase reporter plasmid containing ~2.4 Kb of the 
CYP2B1 5’-flanking region has been previously described (Kocarek et al., 1998). An 
expression plasmid (pExpress-1) containing the rat PPAPDC2 cDNA sequence (Mammalian 
Gene Collection Clone ID 7125531) and a cloning plasmid (pBluescript) containing the human 
PPAPDC2 cDNA (Mammalian Gene Collection Clone ID 5268486) were purchased from GE 
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Healthcare (Pittsburgh, PA). An expression plasmid for human PPAPDC2 was prepared as 
follows. PCR was performed using the plasmid containing human PPAPDC2 cDNA as 
template, Pfu polymerase (Stratagene Cloning Systems; La Jolla, CA), and the following 
primer pairs: forward 5’-GCG AGCGGCCGCGCCACCATGCCAAGTCCCCGGAGGA-3’ 
and reverse                       5’-GCGAGGATCCTCATCGTTGACTCCACAGT-3’ to amplify 
the coding region of human PPAPDC2 (nt 83 to 970 of NCBI Reference Sequence 
NM_203453.3). The PCR product was digested with NotI and BamHI and ligated into the 
corresponding sites of the pE1.1 vector (O.D. 260 Inc.; Boise, ID), into which the 
cytomegalovirus promoter and bovine growth hormone polyadenylation sequences of 
pcDNA3.1 had been pre-ligated at the BglII and Acc65I/KpnI sites, respectively. The sequence 
of this clone (and others described below that were derived by PCR) was verified by the 
Applied Genomics Technology Center at Wayne State University. 
 Twenty-four hr after plating, cell culture medium was replaced and hepatocytes were 
transiently transfected with Williams’ Medium E containing 0.2ml of OptiMEM (Life 
Technologies; Grand Island, NY) and a premixed complex of Lipofectamine 2000 (4 µL), the 
CYP2B1 reporter plasmid (1.2 µg), rat or human PPAPDC2 expression plasmid (50 ng), pRL-
CMV Renilla luciferase reporter plasmid (1 ng), and pBlueScript II KS+ (350 ng) (Agilent 
Technologies; Santa Clara, CA) to adjust total DNA content to 1.6 µg. Five hr following 
transfection, medium was replaced with Williams' Medium E containing 0.8 mg/ml Matrigel. 
Drug treatments were begun the following day and repeated once after 24 hr. Hepatocytes were 
harvested 48 hr after initial treatment for measurement of luciferase activities using the Dual 
Luciferase Reporter Assay System and a GloMax luminometer (Promega Corporation; 
Madison, WI) according to the manufacturer’s instructions. Luciferase data were calculated as 
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firefly/Renilla ratios and presented as described in the figure legends. Experiments were 
repeated in four independent rat hepatocyte preparations.  
PPAPDC2 knockdown by transient transfection in primary cultured rat hepatocytes 
 Four plasmids expressing 29-mer shRNAs targeting rat PPAPDC2 and a non-targeting 
shRNA plasmid (TR30012) were purchased from Origene Technologies (Rockville, MD). A 
validation vector (rPPAPDC2-Luc) was additionally prepared to evaluate knockdown of rat 
PPAPDC2. To prepare this vector, the rat PPAPDC2 expression plasmid described above was 
used as a template to amplify the rat PPAPDC2 cDNA using the forward primer 5’-
GCGAGCGGCCGCGCCACC CGGAGGACTATCGAGGGAC-3’ and reverse primer 5’-
GCGATAGCGGCCGC CTGGATGGCTCTGGCTTAGG-3’ and Pfu polymerase to amplify 
the coding region of rat PPAPDC2 (nt 64 to 1014 of NCBI Reference Sequence 
NM_001034854.1). The PCR product was digested with NotI and ligated into the 
corresponding site of the pCMV-LUC validation vector (TR30004; Origene Technologies), 
which is located downstream of the firefly luciferase coding region. 
 To evaluate the abilities of the different shRNA constructs to knock down PPAPDC2, 
primary cultured rat hepatocytes were incubated in Williams’ Medium E containing 0.2 ml of 
OptiMEM containing a premixed complex of 4 µl Lipofectamine 2000 with 50 ng PPAPDC2 
validation vector, 200 ng of a PPAPDC2-targeting or non-targeting shRNA expression 
plasmid, 1 ng of pRL-CMV Renilla luciferase reporter plasmid, and 1350 ng of pBlueScript II 
KS+. Five hr following transfection, culture medium was replaced with Williams' Medium E 
containing 0.8 mg/ml Matrigel. The cells were then harvested 48 hr after transfection, and 
luciferase activities were measured as described above. The shRNA construct that produced 
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the largest reduction in reporter activity compared to non-targeting control was TI713339, and 
this construct was used for further experiments. 
 To evaluate the effect of PPAPDC2 knockdown on SQ1-mediated CAR activation, 
primary cultured rat hepatocytes were transfected as described above, but using 1.2 µg of 
CYP2B1 reporter plasmid, 200 ng of shRNA construct (PPAPDC2-targeting or non-targeting), 
and 200 ng pBluescript II KS+. After transfection and overnight incubation with Williams' 
Medium E containing Matrigel, drug treatments were performed as described in the individual 
figure legends (three wells per treatment group), repeated once after 24 hr. Forty-eight hr 
following initial treatment, cells were harvested for measurement of luciferase activities. 
PPAPDC2 overexpression by adenoviral transduction in primary cultured rat 
hepatocytes  
The generation of a recombinant adenovirus for expression of rat PPAPDC2 
(Ad5.CMV-PPAPDC2) was performed as described below. The expression plasmid for rat 
PPAPDC2 described above was used as template to amplify rat PPAPDC2 cDNA using the 
following primers: forward primer 5’- GCGAGCGGCCGCGAAGCCTGTCTCCGGTCTG -
3’ and reverse primer 5’-GCGGGATCCGGATGGCTCTGGCTTAGGT -3’ and Pfu 
polymerase to amplify the coding region of rat PPAPDC2 (nt 2 to 1012 of NCBI Reference 
Sequence NM_001034854.1). The PCR product was ligated into the NotI and BamHI sites of 
the pE1.1 shuttle vector, containing the cytomegalovirus promoter and bovine growth hormone 
polyadenylation sequences, as described above. This shuttle plasmid was then provided to O.D. 
260 Inc., who prepared the recombinant adenovirus expressing rat PPAPDC2 (Ad5.CMV-
PPAPDC2). The titer of the recombinant adenovirus as well as of the control adenovirus (Ad-
375; O.D. 260 Inc.) was determined using the QuickTiter Adenovirus Titer ELISA Kit (Cell 
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Biolabs, Inc.; San Diego, CA). Twenty-four hr following plating, primary cultured rat 
hepatocytes were transduced with Ad5.CMV-PPAPDC2 or control adenovirus without insert 
(Ad-375) at a multiplicity of infection of 5. After 5 hr of infection, medium was replaced with 
Williams' Medium E containing 0.8 mg/ml Matrigel. Drug treatments were begun 24 hr after 
infection (two wells per treatment group), and treatments were repeated once after 24 hr. Forty-
eight hr following the initial treatments, cells were harvested for RNA or protein extraction as 
described below. 
Quantitative reverse-transcription polymerase chain reaction analysis  
Primary cultured rat hepatocytes were harvested and total RNA was extracted and 
column purified using the Purelink RNA isolation kit (Ambion; Carlsbad, CA). cDNA was 
synthesized using the High-Capacity cDNA Reverse Transcription Kit (Life Technologies), 
following the manufacturer’s instructions. Primers used to detect CYP2B1 (Forward – 5’-
CAACCCTTGATGACCGCAGTA-3' and Reverse – 5’- TTCAGTGTTCTTGGGAAGCAG 
-3') and primers for the TATA box-binding protein (TBP; Assay ID Rn.PT.51.24118050) were 
purchased from Integrated DNA Technologies (IDT; Coralville, IA). CYP2B1 mRNA levels 
were measured using Power SYBR Green Master Mix in the StepOne Plus Real Time PCR 
System (Applied Biosystems; Foster City, CA). The concentration of each primer was 150 nM, 
and the real-time cycling conditions were: Initial activation step at 95 ºC (15 min) and 40 cycles 
of melting (95 ºC, 15 s) and annealing/extension (60 ºC, 1 min). Relative changes in mRNA 
levels were quantified using the comparative CT (ΔΔCT) method (User bulletin no.2, Applied 
Biosystems). All assays were performed in duplicate in four independent experiments. 
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Western blot analysis 
After 48 hr of treatment, cultured hepatocytes were incubated with gentle agitation on 
ice for 60 min with ice-cold phosphate-buffered saline (PBS) containing 5 mM EDTA to 
dissolve the Matrigel. The cells were then scraped into tubes and centrifuged briefly at 1000 
rpm for 5 min at 4º C. Supernatants were aspirated and cells washed twice with ice-cold PBS. 
Following the final wash, cells were lysed in ice-cold RIPA buffer [50 mM Tris, 150 mM 
NaCl, 0.2% sodium dodecyl sulfate (SDS), 0.25% sodium deoxycholate, 1% Triton X-100, 1 
mM EDTA] containing Halt Protease Inhibitor Cocktail (ThermoFisher Scientific; Rockford, 
IL) by passing the suspension through a 24 gauge needle several times. After extensive 
vortexing, the lysates were centrifuged at 14,000 x g for 15 min at 4 °C and the protein 
concentrations of the supernatants were determined using the bicinchoninic acid assay (Sigma-
Aldrich; St. Louis, MO) with bovine serum albumin as the standard. Lysate samples (20 µg 
protein) were diluted in Laemmli Sample Buffer, denatured at 100º C for 5 min, resolved on 
SDS-polyacrylamide gels (10% acrylamide), and electrophoretically transferred onto 
polyvinylidene difluoride membranes (BioRad; Hercules, CA). Following transfer, 
membranes were incubated in blocking buffer [5% nonfat dry milk diluted in Tris-buffered 
saline (10 mM Tris, 150 mM NaCl, pH 7.4) containing 0.05% Tween-20 (TBST)] for 1 hr at 
room temperature and then incubated overnight at 4º C with gentle rocking in blocking buffer 
containing rabbit polyclonal PPAPDC2 antibody (TA306886; Origene Technologies) diluted 
1:15,000. The following day, blots were washed 3 times with TBST and then incubated 1 hr at 
room temperature in blocking buffer containing horseradish peroxidase-conjugated anti-rabbit 
IgG secondary antibody (Santa Cruz Biotechnology; Dallas, TX) diluted 1:20,000. Following 
washing, immunoreactive bands were visualized using enhanced chemiluminescence 
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according to the manufacturer’s instructions (GE Healthcare) and a FluorChem E detection 
system (ProteinSimple, San Jose, CA). Blots were subsequently incubated in stripping buffer 
(0.1 mM glycine, 1% SDS, 0.05% Tween-20, pH 2.2), blocked, and re-developed with a mouse 
monoclonal β-actin antibody (Sigma-Aldrich) diluted 1:250 in blocking buffer followed by 
anti-mouse IgG secondary antibody diluted 1:20,000 (Santa Cruz Biotechnology). Band 
densities were quantified using ImageJ software (Rasband, 2012). 
Statistical analyses  
Statistical analyses were performed using GraphPad Prism version 6.00 for Mac OS 
X (GraphPad Software; San Diego California USA) to perform two-way analysis of variance 
with the Newman-Keuls correction for multiple comparisons. P<0.05 was considered 
significantly different. All results are presented as mean ± S.E.M. 
3.3 Results 
3.3.1 Overexpression of rat or human PPAPDC2 enhances squalestatin 1-mediated activation 
of a CAR-responsive reporter.   
 Based on the reported ability of PPAPDC2 to dephosphorylate FPP to farnesol 
(Miriyala et al., 2010), we hypothesized that overexpression of PPAPDC2 would enhance 
SQ1-mediated CAR activation in primary cultured rat hepatocytes. Therefore, rat hepatocyte 
cultures were co-transfected with an expression plasmid for PPAPDC2 (rat or human) or empty 
vector and a reporter plasmid containing the CAR-responsive region of CYP2B1 (Kocarek et 
al., 1998) and then treated with 0.1 µM SQ1 or 100 µM PB, the prototype CAR activator. SQ1 
and PB treatment significantly increased CYP2B1 reporter activity by 7.1- and 22-fold, 
respectively, compared to untreated control in hepatocytes transfected with empty vector 
(Figure 3.1A). Therefore, rat and human PPAPDC2, which share 89% amino acid sequence 
	   67	  
	  
similarity, were functionally comparable in their abilities to enhance SQ1-inducible CAR 
activation. PPAPDC2 overexpression did not affect reporter activity in either untreated or PB-
treated hepatocytes, indicating that PPAPDC2 had no direct effect on CAR activity, but rather 
mediated its effect through the mevalonate pathway. Co-treatment of rat hepatocytes with the 
HMGCR inhibitor pravastatin (30 µM), which blocks production of mevalonate (and therefore 
FPP), abolished the effect of SQ1, without or with PPAPDC2 overexpression, on CAR activity 
(Figure 3.1B), further demonstrating the dependence of the PPAPDC2-enhanced CAR 
activation on the mevalonate pathway.  
Figure 3.1  
3.1. Effect of PPAPDC2 overexpression on SQ1-mediated CAR activation in primary 
cultured rat hepatocytes. (A) Twenty-four hr old primary cultures of rat hepatocytes were 
transiently transfected with a CAR-responsive reporter plasmid (CYP2B1-Luc) and either an 
empty expression plasmid (Empty) or an expression plasmid for rat (rPPAPDC2) or human 
PPAPDC2 (hPPAPDC2). Then, 24 hr after transfection, cultures were incubated in medium 
alone (UT) or containing 0.1 µM SQ1 or 100 µM PB. Each bar represents the mean ± S.E.M. 
of the mean normalized (firefly/Renilla) luciferase measurements from four independent 
experiments (n=4). All values are normalized to the Empty:UT group. *Significantly different 
from Empty:SQ1 group, p<0.05; **p<0.01. (B) Rat hepatocytes were co-transfected with 
CYP2B1-Luc and either empty vector (Empty) or rPPAPDC2 and treated with medium alone 
(UT), 0.1 µM SQ1, 0.1 µM SQ1 and 30 µM pravastatin (Prava), or 100 µM PB. Forty-eight hr 
after drug treatment, transfected cultures were harvested for measurement of luciferase 
activity. Each bar represents the mean ± S.E.M. of mean normalized (firefly/Renilla) luciferase 
measurements from three independent experiments (n=3). All values are normalized to the 
Empty:UT group. *Significantly different from the Empty:SQ1 group, p<0.05. 
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3.3.2 Adenovirus-mediated overexpression of rat PPAPDC2 increases squalestatin 1-
inducible CYP2B1 mRNA expression in primary rat hepatocytes. 
 As a complementary approach to plasmid-mediated overexpression of PPAPDC2, we 
used a recombinant adenovirus to overexpress rat PPAPDC2 (Ad5.CMV-PPAPDC2) in 
primary cultured rat hepatocytes and measured CYP2B1 mRNA levels as a marker of CAR 
activation. Transduction with PPAPDC2 at a multiplicity of infection of 5 resulted in a ~2.2-
fold increase in PPAPDC2 immunoreactive protein content relative to that measured in empty 
adenoviral control vector-transduced cells after 48 hr (Figure 3.2A). SQ1 treatment increased 
CYP2B1 mRNA content by ~27-fold in hepatocytes transduced with control vector and ~38-
fold in PPAPDC2-transduced cells (Figure 3.2B), for a significant 1.4-fold enhancement of 
SQ1-mediated CYP2B1 mRNA induction. 
3.3.3 Selection of the most effective PPAPDC2 shRNA to achieve maximal rat PPADPC2 
knockdown.  
The above data show that supplementing the rat hepatocyte’s capacity to convert FPP 
to farnesol increased the ability of a drug that causes FPP accumulation to activate CAR, 
suggesting that FPP dephosphorylation to farnesol is a necessary step in the mechanism by 
which SQ1 treatment activates CAR. However, these data do not address whether PPAPDC2 
is a major enzyme that normally performs this function in hepatocytes. For this, we decided to 
knock down PPAPDC2 using shRNA expression plasmids (non-targeting and PPAPDC2-
targeting) in primary rat hepatocytes. In order to select the best shRNA to achieve maximum 
knockdown efficiency, we first co-transfected primary rat hepatocytes with either of the four 
rat PPAPDC2-targeting shRNA or a non-targeting shRNA along with the rat PPAPDC2 
validation vector as described in methods. As seen in the Figure 3.3, transfection with the all 
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four shRNAs suppressed the luciferase reporter activity compared to the empty control with 
shrPPAPDC2-3 producing the maximal effect. Therefore, this shRNA was selected to perform 
the knock down experiments.  
 
Figure 3.2 
 
  
 
 
 
 
 
 
 
 
Figure 3.2 Effect of adenovirus-mediated overexpression of rat PPAPDC2 on SQ1-
mediated CAR activation in primary cultured rat hepatocytes  
 Rat hepatocytes were transduced with empty adenoviral vector (Ad-375) or adenoviral vector 
expressing rPPAPDC2 (Ad5.CMV-PPAPDC2) and harvested after 48 hr for measurement of 
either rat PPAPDC2 or β-actin protein. The bar graph shows band intensity quantification of 
PPAPDC2 levels normalized to β-actin. (D) Rat hepatocytes were transduced with empty 
adenoviral vector (Ad-375) or adenoviral vector expressing rPPAPDC2 (Ad5.CMV-
PPAPDC2), treated for 48 hr with medium alone (UT) or 0.1 µM SQ1, and harvested for 
measurement of CYP2B1 mRNA levels. Each bar represents the mean CYP2B1 levels ± S.E.M 
from four independent experiments normalized to the Ad-375:UT group (n=4). * Significantly 
different from Ad-375:SQ1 group, p<0.05. 
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Figure 3.3 
 
 
 
Figure 3.3 Selection of the PPAPDC2 shRNA producing maximal rat PPADPC2 
knockdown. Twenty-four hr after plating, primary cultured rat hepatocytes were transiently 
transfected with a validation reporter vector for rat PPAPDC2 (rPPAPDC2-Luc) and either a 
non-targeting control shRNA (shNT) or one of the four shRNAs targeting rat PPAPDC2 
(shrPPAPDC2-1, shrPPAPDC2-2, shrPPAPDC2-3 or shrPPAPDC2-4). After 48 hr, 
hepatocytes were harvested for measurement of luciferase activity. Each bar represents the 
mean ± S.E.M. of mean normalized (firefly/Renilla) luciferase measurements from three 
independent experiments. 
 
3.3.4 PPAPDC2 knockdown attenuates squalestatin 1-mediated activation of the CAR-
responsive reporter. 
 We evaluated the impact of knocking down PPAPDC2 on SQ1-mediated CAR 
activation by performing co-transfections with shRNA expression plasmids (non-targeting and 
PPAPDC2-targeting) and the CYP2B1 reporter plasmid. Transfection with the shRNA that 
produced the greatest knockdown of PPAPDC2 in a validation vector reporter assay (~62% 
reduction, Figure 3.4A) significantly attenuated SQ1-inducible CYP2B1 reporter activation 
(~80% reduction, Figure 3.4B), indicating that PPAPDC2 plays an essential role in SQ1-
mediated CAR activation in primary cultured rat hepatocytes.  
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Figure 3.4  
 
                       
 
 
 
 
 
 
 
Figure 3.4 Effect of PPAPDC2 knockdown on SQ1-mediated CAR activation in primary 
cultured rat hepatocytes. (A) Validation of rPPAPDC2 knockdown: Twenty-four hr after 
plating, primary cultured rat hepatocytes were transiently transfected with a validation reporter 
vector for rat PPAPDC2 (rPPAPDC2-Luc) and either a non-targeting control shRNA (shNT) 
or a shRNA targeting rat PPAPDC2 (shrPPAPDC2). After 48 hr, hepatocytes were harvested 
for measurement of luciferase activity. Each bar represents the mean ± S.E.M. of mean 
normalized (firefly/Renilla) luciferase measurements from three independent experiments 
(n=3). (B) Rat hepatocytes were transiently transfected with the CYP2B1-Luc reporter and 
either the shNT or shrPPAPDC2 plasmid. Then, 24 hr after transfection cultures were 
incubated for 48 hr in medium alone (UT) or containing 0.1 µM SQ1 and harvested for 
measurement of luciferase activity. Each bar represents the mean ± S.E.M. of mean normalized 
(firefly/Renilla) luciferase measurements from three independent experiments (n=3). All 
values are normalized to the shNT:UT group. *Significantly different than the shNT:SQ1 
group, p<0.05. 
 
  
UT SQ1
0
3
6
9
12
15
18
21
24
R
el
at
iv
e 
C
YP
2B
1-
Lu
c 
ac
tiv
ity
(F
ire
fly
/R
en
ill
a)
shNT
shrPPAPDC2
*
shNT shrPPAPDC2
0.00
0.25
0.50
0.75
1.00
1.25
R
el
at
iv
e 
rP
PA
PD
C
2-
Lu
c 
ac
tiv
ity
(F
ire
fly
/R
en
ill
a)
A 
 
B 
 
	   72	  
	  
3.4 Discussion 
 The existence of one or more hepatic enzymes capable of catalyzing FPP 
dephosphorylation is apparent since squalene synthase inhibition causes accumulation of 
farnesol and farnesol-derived metabolites (Bostedor et al., 1997; Vaidya et al., 1998). In 
seeking such enzyme, Christophe and Popjack first described a metal ion-independent prenyl 
pyrophosphatase in rat liver microsome (Christophe and Popják, 1961). Subsequent studies in 
rat microsomes (Bansal and Vaidya, 1994) and in rice seedlings (Nah et al., 2001) identified 
two of these allyl pyrophosphates; farnesyl pyrophosphatase (FPPase) and geranylgeradenyl 
pyrophosphatase (GPPase) that could potentially dephosphorylate FPP to farnesol and GGPP 
to geranylgeranol respectively. Later, phosphatidic acid phosphatase domain containing 2 
(PPAPDC2/PDP1) protein was identified through in vitro assays as the first lipid phosphate 
phosphohydrolase that metabolized presqualene diphosphate (PDSP) to presqualene 
monophosphate and FPP to farnesol with a substrate preference of PSDP > FDP > phosphatidic 
acid (Fukunaga et al., 2006). Further analysis by these investigators showed that the 
diphosphate phosphatase activity of PPAPDC2 was Mg2+-independent, contained a consensus 
catalytic motif for lipid phosphate phosphohydrolase, and had widespread expression in human 
tissues.  
 Our data demonstrate that PPAPDC2 plays an essential role in the mechanism by which 
SQ1 treatment causes CAR activation in primary cultured rat hepatocytes, most likely by 
catalyzing the conversion of FPP to farnesol, which is then itself or a precursor of the active 
endogenous CAR activator. Miriyala et al. (Miriyala et al., 2010) established that PPAPDC2 
catalyzes FPP dephosphorylation and that its overexpression can modulate FPP-dependent 
cellular processes. Overexpression of PPAPDC2 in yeast or mammalian cells decreased FPP 
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levels and caused cytotoxicity. In HEK293 cells, overexpression of PPAPDC2 but not a 
catalytically defective mutant caused cytostasis and accumulation of multinucleate cells. In 
mouse aortic vascular smooth muscle cells, PPAPDC2 overexpression affected processes 
associated with Rho family GTPase function, which is dependent on protein prenylation. Our 
data are the first to link PPAPDC2 to a signaling mechanism in normal hepatocytes.  
 Non-sterol isoprenoids play important roles in a variety of biological processes, and the 
control of their cellular levels is therefore an important therapeutic approach for several 
pathologies (Buhaescu and Izzedine, 2007; Oldfield, 2010; Li et al., 2012). For example, the 
nitrogen-containing bisphosphonate class of drugs (e.g., alendronate, ibandronate) are first line 
treatments for osteoporosis that produce their therapeutic effects by inhibiting FPP synthase, 
and therefore production of FPP and its metabolites, including GGPP. Therefore, the 
bisphosphonates reduce geranylgeranylation of small GTPase proteins in the osteoclast, which 
leads to osteoclast apoptosis (Drake et al., 2015).  
 The isoprenols farnesol and geranylgeraniol themselves have been implicated in 
several biological processes; for example, farnesol as a non-sterol regulator of HMGCR, which 
is a rate-limiting enzyme of mevalonate pathway for sterol biosynthesis.  (Correll et al., 1994; 
Meigs and Simoni, 1997), and these alcohols can be converted back to FPP and GGPP through 
sequential monophosphorylation reactions (Thai et al., 1999). Therefore, the mechanisms 
controlling the interconversion of FPP and farnesol are likely important determinants of 
isoprenoid-regulated cellular processes, and our findings provide further insight into the role 
of PPAPDC2 as a modulator of hepatic physiology. It would be interesting to explore the effect 
of PPAPDC2 on other isoprenoids-regulated cellular mechanisms.  Recent discovery novel 
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PPAPDC family lipid phosphatases inhibitors may provide additional tools to analyze 
additional functional role of PPAPDC2 in the future (Subramanian et al., 2014). 
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CHAPTER 4: CONCLUSIONS 
  Farnesol, one of the sesquiterpene isoprenols, is produced endogenously from 
dephosphorylation of farnesyl pyrophosphate (FPP), which is one of the intermediary 
metabolite of the mevalonate pathway for cholesterol synthesis (Goldstein and Brown, 1990). 
While it was shown recently that the enzyme PPAPDC2 is capable of dephosphorylating FPP 
to produce farnesol, its physiological significance has not been well understood (Miriyala et 
al., 2010). Therefore, one of the objectives of this project was to determine whether the enzyme 
PPAPDC2 has any effects on farnesol-mediated cellular processes that require conversion of 
FPP to farnesol.  
 FPP is metabolized to squalene by the enzyme squalene synthase (SS) in the first 
committed step towards cholesterol synthesis. Based on previous data from our lab, which 
showed that treatment with SQ1 results in the activation of the constitutive androstane receptor 
(CAR), a physiological response that requires accumulation of FPP and farnesol on primary 
cultured rat hepatocytes (Kocarek and Mercer-Haines, 2002), we hypothesized that 
overexpression of PPAPDC2 would enhance SQ1-mediated induction of the CAR target gene, 
CYP2B1. Our hypothesis was validated by our data, which showed that overexpression of 
PPAPDC2 in primary cultured rat hepatocytes results in significantly increased CAR activity 
as well as increased expression of the CYP2B1 mRNA. Also, knockdown of endogenous 
PPAPDC2 suppressed the SQ1-mediated induction of CAR activity demonstrating that 
PPAPDC2 plays an important role in SQ1-induced CAR activity in rat hepatocytes, most 
probably by mediating the conversion of FPP to farnesol. This finding provides a physiological 
significance to PPAPDC2 and its catalytic ability to dephosphorylate FPP to farnesol. 
Measurement of farnesol levels in PPAPDC2-overexpressed rat hepatocytes is recommended 
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for further analysis to show that PPAPDC2 is increasing farnesol levels in primary cultured rat 
hepatocytes. 
 Based on the published findings that farnesol regulates lipid metabolism in rodents and 
reduces hepatic accumulation of triglycerides through activation of peroxisome proliferator 
receptor alpha (PPARα) and farnesol X receptor (FXR), we hypothesized that farnesol has 
similar effects on human hepatocytes and that these effects occur through any or all of the 
nuclear receptors, PPARα, FXR and CAR. In order to test our hypothesis, we established a 
human hepatic cellular model for steatosis by incubating HepaRG cells with oleic acid (OA), 
a known inducer of steatosis. Treatment with farnesol (100µM) significantly reduced the OA-
induced accumulation of TGs in HepaRG cell cultures. Farnesol increased the activity of 
PPARα and CAR in HepaRG cells and had no effect on FXR activity.  
 Customized array analysis of 85 genes involved in the regulation of human hepatic 
lipid metabolism showed that farnesol changes expression of several hepatic lipid-
metabolizing enzymes, a majority of which belonged to the fatty acid oxidation pathway. Few 
other enzymes that regulate lipogenesis, fatty acid uptake and transport and export were also 
changed. Activation of CAR had no substantial effect on the expression of genes studied; while 
activation of FXR changed expression of genes including PPARγ and PCK1, whose primary 
functions are adipocyte differentiation and glucose homeostasis respectively. However, 
treatment with the PPARα agonist changed expression of several genes, most of which were 
involved in fatty acid oxidation, transport, uptake and export. Additionally, most of the 
farnesol-mediated changes in gene expression in control or OA-overloaded HepaRG cells were 
similar to that achieved through activation of PPARα. Further analysis revealed that farnesol 
activated fatty acid oxidation in HepaRG cells under steatogenic conditions. Farnesol also 
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increased the mRNA levels of genes involved in mitochondrial fatty acid oxidation, which was 
mediated through PPARα. Additionally, farnesol attenuated OA-induced alteration in the 
expression of drug-metabolizing enzymes.  
 Isoprenols, such as farnesol are natural compounds that are ubiquitously present in 
higher plants and in addition to lipid metabolism, dietary intake of several isoprenoids have 
been implicated in several other physiological processes, such as inhibition of tumor 
proliferation, initiation of apoptosis and cellular differentiation. Here, we provide evidence that 
farnesol can potentially ameliorate OA-induced TG accumulation in human hepatocytes and 
could be beneficial in reversing changes in the expression of hepatic enzymes involved in drug 
metabolism. While it is too early to recommend intake of farnesol or its dietary sources as a 
potential therapeutic approach against metabolic diseases, such as non-alcoholic fatty liver 
disease where hepatic TG accumulation is the major symptom or cause for disease 
pathogenesis, our data as well as data from previously published animal models warrants a 
more in-depth investigation in order to further elucidate any potential beneficial effects of 
farnesol and other isoprenoids.  
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APPENDIX 
Appendix A. List of lipid metabolizing genes in the custom RT2 ProfilorTM PCR Array. 
Pathway Symbol Gene Name 
Triglyceride 
Biosynthesis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fatty acid 
synthesis 
AGPAT1 1-acylglycerol-3-phosphate O-acyltransferase 1 (lysophosphatidic acid 
acyltransferase, alpha) 
AGPAT2 1-acylglycerol-3-phosphate O-acyltransferase 2 (lysophosphatidic acid 
acyltransferase, beta) 
AGPAT6 1-acylglycerol-3-phosphate O-acyltransferase 6 (lysophosphatidic acid 
acyltransferase, zeta) 
AGPAT9 1-acylglycerol-3-phosphate O-acyltransferase 9 
DGAT1 Diacylglycerol O-acyltransferase 1 
DGAT2 Diacylglycerol O-acyltransferase 2 
GPAT2 Glycerol-3-Phosphate Acyltransferase 2, Mitochondrial 
LPIN1 Lipin 1 
LPIN2 Lipin 2 
LPIN3 Lipin 3 
ACAA2 Acetyl-CoA acyltransferase 2 
ACACA Acetyl-CoA carboxylase alpha 
ACACB Acetyl-CoA carboxylase beta 
ACLY ATP citrate lyase 
FASN Fatty acid synthase 
SCD Stearoyl-CoA desaturase  
MECR Mitochondrial Trans-2-Enoyl-CoA Reductase 
ELOVL3 ELOVL fatty acid elongase 3 
ELOVL1 ELOVL fatty acid elongase 1 
ELOVL2 ELOVL fatty acid elongase 2 
ELOVL5 ELOVL fatty acid elongase 5 
MCAT Malonyl CoA:ACP Acyltransferase (Mitochondrial) 
ELOVL4 ELOVL fatty acid elongase 4 
ELOVL6 ELOVL fatty acid elongase 6 
TECR Trans-2,3-Enoyl-CoA Reductase 
SCD5 Stearoyl-CoA desaturase 5 
SREBP-1c Sterol regulatory element-binding transcription factor 1c 
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Pathway Symbol Gene Name 
Fatty acid 
transport 
Fatty a 
CPT1A Carnitine palmitoyltransferase 1A (liver) 
CPT2 Carnitine palmitoyltransferase 2 
FABP1 Fatty acid binding protein 1, liver 
SLC27A1 Solute carrier family 27 (fatty acid transporter), member 1 
Scp2 Sterol Carrier Protein 2 
SLC27A2 Solute carrier family 27 (fatty acid transporter), member 2 
Fatty acid 
oxidation 
ACOT1 Acyl-CoA thioesterase 1 
ACOT12 Acyl-CoA thioesterase 12 
ACOT6 Acyl-CoA thioesterase 6 
ACOT7 Acyl-CoA thioesterase 7 
ACADL Acyl-CoA dehydrogenase, long chain 
Mitochondrial 
fatty acid β-
oxidation 
ACADM Acyl-CoA dehydrogenase, C-4 to C-12 straight chain 
ACADS Acyl-CoA dehydrogenase, C-2 to C-3 short chain 
ACADVL Acyl-CoA dehydrogenase, very long chain 
ACSL3 Acyl-CoA synthetase long-chain family member 3 
ACSL4 Acyl-CoA synthetase long-chain family member 4 
 ACSL5 Acyl-CoA synthetase long-chain family member 5 
 HADH Hydroxyacyl-CoA Dehydrogenase 
 EHHADH Enoyl-CoA, hydratase/3-hydroxyacyl CoA dehydrogenase 
 DECR1 2,4-Dienoyl CoA Reductase 1, Mitochondrial 
 ECHS1 Enoyl CoA Hydratase, Short Chain, 1, Mitochondrial 
 HADHA Hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA 
thiolase/enoyl-CoA hydratase (trifunctional protein), alpha 
subunit 
 SLC25a20 Solute Carrier Family 25 (Carnitine/Acylcarnitine Translocase), 
Member 20 
 HADHB Hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA 
thiolase/enoyl-CoA hydratase (trifunctional protein), beta 
subunit 
Perioxisomal 
β-oxidation  
ACOT4 Acyl-CoA thioesterase 4 
ACOT8 Acyl-CoA thioesterase 8 
ACOX1 Acyl-CoA oxidase 1, palmitoyl 
ACOX2 Acyl-CoA oxidase 2, branched chain 
ECH1 Enoyl CoA Hydratase 1, Peroxisomal 
PECR Peroxisomal Trans-2-Enoyl-CoA Reductase 
Microsomal 
oxidation 
CYP4A11 Cytochrome P450, family 4, subfamily A, polypeptide 11 
CYP2E1 Cytochrome P450, family 2, subfamily E, polypeptide 1 
Lipoprotein 
Assembly 
ApoB Apolipoprotein B 
ApoC4 Apolipoprotein C-IV 
ApoE Apolipoprotein E 
MTTP Microsomal triglyceride transfer protein 
ApoA5 Apolipoprotein A-V 
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Pathway Symbol Gene Name 
Carbohydrate 
metabolism 
PEPCK-C Phosphoenolpyruvate Carboxykinase 1 (Soluble) (PCK1) 
ChREBP MLX Interacting Protein-Like 
Inflammation IL6 Interleukin-6 
TNFA Tumor Necrosis Factor α 
Nuclear 
receptors 
PPARG Peroxisome Proliferator-Activated Receptor Gamma 
PPARA Peroxisome Proliferator-Activated Receptor Alpha 
CAR Constitutive androstane receptor (NR1I3) 
FXR Farnesol X receptor (NR1H4) 
Positive targets CYP2B6 Cytochrome P450, Family 2, Subfamily B, Polypeptide 6 
SHP Short heterodimer partner (NR0B2) 
PLIN2 Perilipin 2 
Internal 
Controls 
  
TBP TATA binding protein 
HPRT1 Hypoxanthine Phosphoribosyltransferase 1 
UBC Ubiquitin C 
GAPDH Glyceraldehyde-3-Phosphate Dehydrogenase 
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Appendix B:  Customized gene array analysis data to measure the changes in the 
expression of hepatic lipid metabolizing genes in response to drug treatment in HepaRG 
cells.  
Gene CITCO GW4064 GW7674 FOH OA OA+
FOH 
ACAA1 0.8799 0.8395 1.6479 0.8655 0.9721 1.2377 
ACAA2 0.9347 1.1325 2.0272 1.3062 1.3093 1.7096 
ACACA 0.9855 1.0217 0.9994 0.8224 0.796 1.0945 
ACACB 1.2172 1.0401 1.4265 0.7267 0.9187 1.153 
ACADL 0.8675 0.8112 0.9124 1.1088 0.8857 0.9287 
ACADM 1.0541 0.923 1.5619 1.2027 1.1132 1.282 
ACADS 1.5445 1.4987 2.6926 1.017 1.3195 2.1444 
ACADVL 0.9145 1.0013 1.5042 0.9845 1.1023 1.0624 
ACAT1 1.0067 0.8273 1.2435 1.286 1.0937 1.1318 
ACAT2 0.9109 0.9704 0.8419 1.2942 1.118 1.0567 
ACLY 0.983 1.1091 0.942 0.9378 0.8512 1.1155 
ACOT1 1.2821 1.1718 1.5341 0.8993 1.0454 1.229 
ACOT12 1.3941 0.8307 1.6284 1.5955 1.7735 3.627 
ACOT4 0.8704 0.7416 0.8807 1.0631 0.8421 0.9859 
ACOT6 0.7218 0.6051 0.8094 0.9515 0.9337 0.7654 
ACOT7 0.9654 1.0757 0.8729 1.0072 0.9008 0.8302 
ACOT8 1.2356 1.1937 1.1652 0.8135 0.8991 1.1978 
ACOX1 1.077 1.0202 1.3298 1.0728 0.9511 1.2925 
ACOX2 1.0382 0.3606 1.2547 1.6993 0.7377 0.8591 
ACSL3 0.9464 1.3041 1.3998 1.233 0.8494 0.9014 
ACSL4 1.1188 0.9977 1.5984 0.9094 0.9711 1.3526 
ACSL5 1.0347 1.6047 1.6668 1.2421 1.0974 1.4553 
AGPAT1 0.9936 1.2626 1.0302 0.8698 0.8427 0.7275 
AGPAT2 1.3003 1.5271 1.8207 0.7344 1.3935 1.1894 
AGPAT6 1.0296 1.2749 1.1236 0.8133 0.9999 1.359 
AGPAT9 1.2439 1.3468 1.3221 0.7875 1.3372 1.2009 
APOA5 0.9963 1.6219 1.8338 1.3167 2.526 4.2487 
CD36 0.7472 0.9812 3.3505 1.084 1.5526 1.1457 
COX10 1.034 0.9851 1.0598 0.7541 0.9051 1.1201 
CPT1A 1.193 1.1223 1.8485 0.9746 1.1953 1.6018 
CPT2 1.0877 0.9595 1.507 0.9741 0.9289 1.0363 
CYP2B6 8.2174 0.545 0.8278 1.9403 0.6128 2.056 
CYP2E1 1.107 0.1995 1.0143 0.6968 1.2519 1.8636 
CYP4A11 0.7328 0.4687 1.6903 0.9773 0.8708 0.9523 
DGAT1 0.9348 0.5121 1.0708 0.777 0.8172 0.9472 
DGAT2 1.1081 0.7129 1.196 0.8543 1.0491 1.2013 
DHDDS 1.0441 1.2125 1.393 0.8875 1.1887 1.1632 
EHHADH 1.0448 0.8354 1.288 0.9608 0.9764 1.2051 
ELOVL3 2.993 1.5148 1.1878 1.4067 1.258 2.7722 
ELOVL4 0.1089 0.1152 0.1193 1.4714 0.0834 0.096 
ELOVL6 1.0914 1.0433 1.006 0.9558 1.0966 1.3819 
FABP1 1.1298 0.7115 3.2373 1.8436 0.7531 1.2149 
FASN 1.2928 1.3251 1.2404 0.9336 0.8057 1.2358 
FDFT1 0.9353 1.0537 0.9788 1.3802 0.9781 0.9908 
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Gene CITCO GW4064 GW7674 FOH OA OA+ 
FOH 
FDPS 0.8407 0.8519 0.9092 1.2214 0.8785 0.8394 
FNTA 1.0159 0.8528 1.1345 0.8509 0.8971 1.233 
FNTB 1.0901 1.1414 1.0968 0.7507 0.9045 1.1704 
GGPS1 1.0164 1.1227 1.0335 1.1131 0.8738 0.9109 
GPAT2 0.9084 0.859 0.8897 1.143 0.6411 0.7161 
HADHA 0.8736 0.8788 1.8146 1.0476 1.178 1.315 
HADHB 1.0243 1.0516 2.4506 1.2409 1.553 1.4498 
HMGCR 0.9768 1.1588 0.9515 1.1232 1.1961 1.3589 
IL6 0.9854 1.0259 0.7691 0.8693 0.52 1.052 
LIPC 0.9222 0.4976 1.2883 1.3079 0.8627 0.9827 
LPIN1 0.9997 0.8405 1.0866 0.8298 0.9478 1.2515 
LPIN2 1.0402 0.8091 1.1049 0.8216 0.8378 1.1673 
LPIN3 0.9026 0.8195 0.9344 0.7582 0.7753 1.061 
NR0B2 0.7507 3.6372 0.4787 0.7553 0.7336 0.5794 
NR1H4 1.0429 0.7239 1.14 1.0094 0.9533 1.1958 
NR1I3 1.1957 0.7971 0.7753 0.7791 0.6958 0.9681 
PCK1 0.9622 0.1389 2.4761 0.6907 1.7774 3.5014 
PDSS1 1.051 0.9585 1.1836 1.3663 1.1598 1.0276 
PLIN2 0.7819 1.0473 3.0052 1.2674 1.4752 1.7641 
PPAPDC2 1.0382 1.1565 1.0054 0.9442 0.847 1.1158 
PPARA 1.3218 1.3823 1.1067 0.9419 1.0846 1.5178 
PPARG 1.0456 2.0577 1.2685 1.428 1.1001 1.2477 
RABGGTA 0.9339 1.0157 0.9041 0.932 0.8326 0.7335 
RABGGTB 0.8281 0.8807 0.9288 1.1707 0.8291 0.7658 
SCD 0.9835 0.6528 1.3653 1.1431 0.4927 0.718 
SCD5 0.8981 1.0085 0.9269 0.7609 0.6957 0.7802 
SLC27A1 1.1283 1.2223 1.0891 0.6898 0.8428 1.1979 
SLC27A2 1.0645 1.177 1.9246 1.6574 0.7996 1.0796 
SREBF1 1.1633 0.9704 1.2816 0.6645 0.6338 0.9466 
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Appendix C. Primer sequences used for RT-qPCR. 
Gene Name Forward primer Reverse Primer 
HADHA Hydroxyacyl-CoA 
dehydrogenase/3-ketoacyl-
CoA thiolase/enoyl-CoA 
hydratase (trifunctional 
protein), alpha subunit 
GGAGGACTTGAGGTTGCCAT TAAGGCCCCCAGC
AAAACTT 
HADHB hydroxyacyl-CoA 
dehydrogenase/3-ketoacyl-
CoA thiolase/enoyl-CoA 
hydratase (trifunctional 
protein), beta subunit 
CCCCAGCTGTCCAGACCAAA CCGATGCAACAAA
CCCGTAA 
ACAA2 Acetyl-CoA acyltransferase 
2 
CAGGGAATGCATCGGGTGTA GCCCACAATTCTT
GCCAGTG 
ACOT12 Acyl-CoA thioesterase 12 TGCTCAAGTGGATCGACACC TCCAACTCTAGCT
GTCTCCTCA 
EHHADH Enoyl-CoA, hydratase/3-
hydroxyacyl CoA 
dehydrogenase 
AAAAGTGGTTTGCCTGACGG AAGTCGTACTGAT
CGCGTTG 
ACOX1 Acyl-CoA oxidase 1, 
palmitoyl 
CTTCAACCCGGAGCTGCTTA ATGTTCTCGATCC
GGCG 
ACOX2 Acyl-CoA oxidase 2, 
branched chain 
ACAGAGGGGAGCCAGGTTCTT ATCCCCCAATGAC
ACTCGGT 
CYP1A2 Cytochrome P450, family 1, 
subfamily A, polypeptide 2 
AGCACCTGCCTCTACAGTTGG TTTTCAGGCCTTTG
GGGACC 
CYP3A4 Cytochrome P450, family 3, 
subfamily A, polypeptide 4 
TACCCAATAAGGCACCACCC 
 
AATGTGCAGGAAA
GCATCTGA 
CYP2E1 Cytochrome P450, family 2, 
subfamily E, polypeptide 1 
ACTCCCTGGCTCCAGCTTTA 
 
TCTCTGTCCCCGCA
AAGAAC 
CYP2B6 Cytochrome P450, family 2, 
subfamily B, polypeptide 6 
AGCTTCATGACCGAGCCAAA CTGTGTCCTTGGG
GATGATGT 
SHP Small heterodimer partner 
(NR0B2) 
GTGGCTTCATGCTGTCTGG CTGGCACATCGGG
GTTGA 
PLIN2 Perilipin 2 GGCGAGGCGGGGTTTATAG 
 
CCACACTCGGTTG
TGGATCA 
PCK1 Phosphoenolpyruvate 
Carboxykinase 1 (Soluble) 
(PEPCK1) 
ATCCCCAAAACAGGCCTCAG ACGTACATGGTGC
GACCTTT 
ACADS Acyl-CoA dehydrogenase, 
C-2 to C-3 short chain 
CCAGGGATGGGCTTCAAGAT TGTCTGCCAACTT
GAACTGGA 
SCD Stearoyl-CoA desaturase TTCCCGACGTGGCTTTTTCT AGCCAGGTTTGTA
GTACCTCC 
SREBP1c Sterol regulatory element-
binding transcription factor 
1c 
GTAACGACCACTGTGACCTCG CACTCACCAGGGT
CGGCAAA 
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ABSTRACT 
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Non-alcoholic fatty liver disease is emerging as one of the most common liver disorders 
worldwide and is characterized by accumulation of triglycerides (TGs) in liver. The 
endogenous isoprenoid farnesol reduces hepatic TG levels in rodents, and this effect appears 
to involve at least two nuclear receptors, peroxisome proliferator-activated receptor α and 
farnesoid X receptor (FXR). However, farnesol’s effects on human hepatic lipid metabolism 
are currently unknown. The objective of this study is to evaluate how farnesol treatment would 
affect hepatic lipid accumulation and metabolism in a cellular model of human hepatic steatosis 
that was created by incubating the hepatocyte-like HepaRG cell line with oleic acid. Farnesol 
treatment suppressed the OA-induced TGs accumulation in HepaRG cells by 25%. Farnesol 
upregulated the activity of lipid-sensing nuclear receptors PPARα and constitutive androstane 
receptor (CAR), which was evident by the increase in the expression of their respective target 
genes, PLIN2 and CYP2B6; however, farnesol had no effect on FXR activity in HepaRG cells. 
Gene expression analysis through customized arrays revealed that farnesol modulated mRNA 
levels of several hepatic lipid- and drug-metabolizing enzymes in both control and OA-
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overloaded HepaRG cells, and the expression pattern was similar to that achieved through 
activation of PPARα rather than through CAR or FXR.  
 In OA-overloaded HepaRG cells, farnesol treatment induced overall fatty acid 
oxidation rate, which was accompanied by upregulation in the mRNA levels of PPARα target 
genes involved in hepatic mitochondrial fatty acid oxidation, such as HADHB, ACADS and 
ACOT12. This effect was lost when cells were co-treated with the PPARα antagonist except 
for ACOT12. Farnesol had no effect on genes regulating peroxisomal oxidation. OA-induced 
changes in drug-metabolizing enzymes, such as CYP3A4, CYP2B6, CYP1A2 and CYP2E1 
were also attenuated by co-treatment with farnesol. Our findings show for the first time that 
farnesol regulates human hepatic lipid metabolism and suppresses lipid accumulation in 
HepaRG cells under steatogenic conditions by upregulating mitochondrial fatty acid oxidation, 
primarily through PPARα pathway.    
 Farnesyl pyrophosphate (FPP) is a branch-point intermediate in the mevalonate 
pathway that is normally converted mainly to squalene by squalene synthase in the first 
committed step of sterol biosynthesis. Treatment with the squalene synthase inhibitor 
squalestatin 1 (SQ1) causes accumulation of FPP, its dephosphorylated metabolite farnesol, 
and several oxidized farnesol-derived metabolites. Also, SQ1 treatment of primary cultured rat 
hepatocytes increases CYP2B expression through a mechanism that requires FPP synthesis 
and activation of the constitutive androstane receptor (CAR). Because direct farnesol treatment 
also increases CYP2B expression, it seems likely that SQ1-mediated CAR activation requires 
FPP dephosphorylation to farnesol. The lipid phosphatase, phosphatidic acid phosphatase 
domain containing 2 (PPAPDC2), was recently reported to catalyze FPP dephosphorylation. 
We therefore determined the effect of overexpressing or knocking down PPAPDC2 on SQ1-
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mediated CAR activation in primary cultured rat hepatocytes. Co-transfection of rat 
hepatocytes with a plasmid expressing rat or human PPAPDC2 enhanced SQ1-mediated 
activation of a CAR-responsive reporter by 1.7- or 2.4-fold over the SQ1-mediated activation 
that was produced when hepatocytes were co-transfected with empty expression plasmid. 
Similarly, transduction of rat hepatocytes with a recombinant adenovirus expressing 
PPAPDC2 enhanced SQ1-mediated CYP2B1 mRNA induction by 1.4-fold over the induction 
that was seen in hepatocytes transduced with control adenovirus. Co-transfection with a 
shRNA targeting PPAPDC2 reduced SQ1-mediated CAR activation by ~80% relative to the 
activation that occurred in hepatocytes transfected with non-targeting shRNA. These results 
indicate that PPAPDC2 plays an important role in SQ1-mediated CAR activation, most 
probably by catalyzing the conversion of FPP to farnesol. 
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